WO2005067818A1 - Rotating balloon expandable sheath bifurcation delivery system - Google Patents

Rotating balloon expandable sheath bifurcation delivery system Download PDF

Info

Publication number
WO2005067818A1
WO2005067818A1 PCT/US2004/034360 US2004034360W WO2005067818A1 WO 2005067818 A1 WO2005067818 A1 WO 2005067818A1 US 2004034360 W US2004034360 W US 2004034360W WO 2005067818 A1 WO2005067818 A1 WO 2005067818A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
end region
proximal
catheter assembly
bmp
Prior art date
Application number
PCT/US2004/034360
Other languages
French (fr)
Inventor
Tracee Eidenschink
Daniel Gregorich
Karl A. Jagger
Original Assignee
Boston Scientific Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Scientific Limited filed Critical Boston Scientific Limited
Priority to JP2006546974A priority Critical patent/JP4740153B2/en
Priority to CA002550529A priority patent/CA2550529A1/en
Priority to EP04795507A priority patent/EP1708644A1/en
Publication of WO2005067818A1 publication Critical patent/WO2005067818A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/856Single tubular stent with a side portal passage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/954Instruments specially adapted for placement or removal of stents or stent-grafts for placing stents or stent-grafts in a bifurcation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958Inflatable balloons for placing stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0076Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures

Definitions

  • Catheter systems such as angioplasty catheters, and stent delivery systems, as well as the stents associated therewith, are widely used in the treatment of stenoses, aneurysms, lesions, and other abnormalities within blood vessels and other body lumens.
  • Intravascular stents are used in coronary, renal, and carotid arteries, for example, to maintain an open passage through the artery.
  • stents In patients whose coronary heart disease consists of focal lesions, stents have proven effective. For example, where only a single coronary artery is clogged or where there are short blockages in more than a single artery, stents have been used with a great amount of success.
  • An intravascular stent may be positioned in a clogged artery by a catheter and is often set in place by inflating a balloon upon which the stent is mounted. This expands the diameter of the stent and opens the previously clogged artery. The balloon is then deflated and removed from the patient while the stent retains an open passage through the artery.
  • Treatment at bifurcation sites has been difficult. Although efforts have been made to use a stent at bifurcations, these sites have previously been problematic to treat.
  • the specialty stents designed for bifurcations generally need specific alignment, radially as well as longitudinally. For example, U.S. Patent No.
  • 5,749,825 is representative of a catheter system that is intended to treat stenoses at an arterial bifurcation.
  • the disclosure of 5,749,825 is hereby incorporated by reference.
  • a stent delivery system employing a stent assembly with branches intended for deployment in the adjacent branches of a vessel bifurcation has been proposed to allow placement of a portion of the assembly in both a primary passage, such as an artery, and a secondary passage, such as a side branch artery. Additionally, these stents generally have an opening which allows for unimpeded blood flow into the side branch artery. However, problems are still encountered in orienting the stent relative to the side branch at the bifurcation of the primary and secondary passages.
  • bifurcated assemblies are typically specially manufactured at an increased cost over a more standard stent intended for single vessel deployment.
  • many current devices rely on either passive torque (e.g., pushing the stent forward and allowing the stent that is fixed on the guidewire/balloon to passively rotate itself into place) or creating torque from outside of the patient to properly orient the medical device in the passage.
  • passive torque e.g., pushing the stent forward and allowing the stent that is fixed on the guidewire/balloon to passively rotate itself into place
  • These devices and methods of achieving proper angular orientation have not been shown to be effective in properly placing and positioning the stent.
  • many catheter systems which are currently utilized to deploy a stent or other implantable device into a body lumen do not provide adequate stent edge protection prior to delivery.
  • Some embodiments of the present invention include a freely rotating deployment assembly for a stent assembly for maintaining side branch access and protection.
  • At least one embodiment of the invention includes a medical device with a balloon catheter shaft and a rotating sheath such as is described in U.S. Patent Application No. 10/375,689, filed February 27, 2003 and U.S. Patent Application No.
  • the sheath has one or more end regions and an intermediate region, wherein the intermediate region has an outer diameter less than that of either or both end regions.
  • the intermediate region defines a stent mounting region wherein the stent is disposed prior to delivery between end regions of the sheath.
  • the catheter further comprises one or more end sleeves or socks, wherein each sleeve has a first end engaged to the catheter shaft adjacent to an end of the balloon. In some embodiments the first end of each sleeve is freely rotatable about the catheter shaft. In at least one embodiment, a sleeve has a second end, which prior to deployment of the stent, is disposed about an end of the stent and during deployment of the stent is retracted therefrom to release the stent into a body lumen.
  • a proximal sleeve is engaged to the proximal end of the stent and a distal sleeve is engaged to a distal end of the stent.
  • a single sleeve is engaged to only one end of the stent prior to deployment.
  • the medical device comprises a secondary guidewire lumen housing, which itself comprises a reinforcing member, such as a polymer tube of PEBAX, peek, polyimide, etc., a braided tube of metal wire or other material, a hypotube, or other device engaged to the sheath and engaged to the collar.
  • an inner member is positioned within the reinforcing member to define the secondary guidewire lumen.
  • the material of the inner member is more flexible than the material of the reinforcing member.
  • the inner member is longer than the reinforcing member and at least one end of the inner member extends beyond at least one end of the reinforcing member.
  • the inner member is concentrically disposed within the reinforcing member.
  • the inner member is asymmetrically disposed within the reinforcing member.
  • the proximal end of the reinforcing member is proximally adjacent to the stent. In some embodiments the proximal end of the reinforcing member is tapered.
  • the reinforcing member is positioned such that at least a portion of the reinforcing member is radially offset from the distal end of the stent.
  • the rotatable sheath has a length longer than the stent.
  • one or both ends of the sheath are folded back over the corresponding ends of the stent prior to delivery. When the stent is deployed the one or both ends of the sheath slidingly retract off of the stent, thereby freeing the ends of the stent for deployment. In some embodiments only the distal end of the sheath is folded over the distal end of the stent prior to delivery.
  • the proximal end of the sheath defines a proximal slit or is tapered to accommodate the position of the secondary guidewire lumen housing, such that the proximal end of the sheath may be folded over at least a portion of the proximal end of the stent prior to delivery.
  • FIG. 1 is a side view of an embodiment of the invention, comprising a rotating sheath assembly.
  • FIG. 2 is a side view of the embodiment shown in FIG. 1 shown configured for delivery of a stent.
  • FIG. 3 is a side view of an embodiment of the invention comprising a catheter assembly. The catheter assembly is provided with a rotating collar.
  • FIG. 4 is a side view of the catheter assembly of FIG. 3 and further comprising the rotating sheath assembly and stent of FIG. 2.
  • FIG. 5 is a side view of an embodiment of the invention wherein the catheter assembly of FIG.
  • FIG. 6 is a side perspective view of an embodiment of the invention comprising a stent, such as that shown in FIG. 2.
  • FIG. 7 is a side perspective view of the stent shown in FIG. 6 wherein a side branch opening is shown formed from the enlargement of a cell opening in the stent wall.
  • FIG. 8 is a cross-sectional view of the stent of FIG. 7.
  • FIG. 9 is a side view of the stent depicted in FIG. 5, wherein the stent has been delivered from the catheter assembly, by balloon expansion and the assembly subsequently withdrawn from the vessel(s).
  • FIG. 10 is a side view of an embodiment of the embodiment of the invention shown in FIG. 4 which includes protective sleeves.
  • FIG. 11 is a cross-sectional view of a portion of the system shown in FIG. 10 corresponding to section A.
  • FIG. 12 is a cross-sectional view of a portion of the system shown in FIG. 10 corresponding to section B.
  • FIG. 13 is a side view of the embodiment shown in FIG. 10 wherein the sleeves have been retracted from the ends of the stent.
  • FIG. 14 is a side view of an embodiment of the invention wherein each end of the rotating sheath is folded over the corresponding end of the stent.
  • FIG. 15 is a side view of the embodiment shown in FIG. 14, wherein the ends of the sheath have been retracted off of the stent.
  • FIG. 16 is a side view of an embodiment of the invention wherein each end of the rotating sheath is folded over the corresponding end of the stent and the proximal end of the sheath defines a slot.
  • FIG. 17 is a side view of the embodiment shown in FIG. 16, wherein the ends of the sheath have been retracted off of the stent.
  • FIG. 18 is a side view of an embodiment of the invention wherein the rotating sheath comprises a pair raised end portions or hubs.
  • FIG. 19 is a side view of an embodiment of the invention shown in FIG. 18 wherein the secondary guidewire housing comprises a bent portion over the proximal hub of the rotating sheath.
  • FIG. 20 is a side view of an embodiment of the invention wherein the rotating sheath comprises a pair raised end portions or hubs, wherein the proximal hub defines a passage for the secondary guidewire housing.
  • FIG. 21 is a side view of an embodiment of the invention wherein the secondary guidewire housing is radially offset from the proximal end of the stent.
  • FIG. 22 is a cross-sectional view of a portion of the system shown in FIG. 21 corresponding to section C.
  • FIG. 23 is a side view of an embodiment of the invention wherein the secondary guidewire housing comprises a step which is radially offset from the proximal end of the stent.
  • FIG. 24 is a side view of an embodiment of the invention wherein the cones of the balloon are provided with a puffed configuration in the unexpanded state.
  • FIG. 25 is a side view of an embodiment of the invention wherein only the distal cone of the balloon is provided with a puffed configuration in the unexpanded state.
  • FIG. 26 is a side view of either of the embodiments shown in FIGs. 24 and 25, wherein the balloon is shown in an expanded state.
  • FIG. 1 a rotating sheath assembly 100 is shown which comprises a tubular sleeve or sheath 102 and a positioning or secondary guidewire housing 104.
  • the housing 104 defines a secondary guidewire lumen 106 through which a secondary guidewire 108 may be passed.
  • the housing 104 maybe constructed of a wide variety of materials including metal plastic, etc., in at least one embodiment the housing 104 is an external reinforcing member or hypotube 64.
  • the hypotube 64 may comprise stainless steel, one or more polymer materials or other material.
  • the housing 104 is provided with one or more openings 110 along its length.
  • the housing 104 is spiral cut to provide at least a continuous opening 110 which acts to provide improve the flexibility of the housing 104.
  • the secondary guidewire housing 104 further comprises an inner shaft 103, about which the hypotube 64 is disposed.
  • the inner shaft 103 is a flexible hollow tubular member which extends distally beyond the distal end of the hypotube 64. This distal and/or proximal tips 105 of the inner shaft 103 provides the housing with a flexible protective sheath about the guidewire 108 as it passes out of the secondary guidewire lumen 106. Such a protective covering prevents the guidewire 108 from excessively rubbing against the wall 201 of the vessel 199, such as in the manner depicted in FIG. 5; even where the secondary guidewire 108 exits the secondary lumen 106 at a significant angle.
  • the inner shaft 103 may be constructed of any of a variety of flexible materials such as: PEBAX, nylon, urethane, and/or other materials in a single layer, multi-layer and/or braided configuration.
  • the shaft 144 of the catheter 116 defines a primary guidewire housing 211 through which a primary guidewire 107 may be advanced.
  • guidewires 107 and 108 are passed through a lumen or other body vessel 209 to a bifurcation 203.
  • Primary guidewire 107 is then advanced into a primary branch of passage 205 of the bifurcation 203 while the secondary guidewire 108 is advanced into the adjacent or secondary branch 207 of the bifurcation 203.
  • the rotatable sleeve 104 will rotate the stent 120 into a desired position so that the secondary opening 130a of the stent is aligned with the secondary passage 207.
  • the system 300 is a fixed wire system, and as such the use of the prinary guidewire is unnecessary.
  • at least a distal portion of the housing 104 is engaged to at / least a proximal portion of the sheath 102 at an engagement site 112.
  • the manner or mechanism of engagement between the sheath and housing 104 may be by bonding, welding, adhering adhesively engaging, mechanically engaging or otherwise connecting the surfaces of the respective sheath 102 and housing 104.
  • the sheath 102 is a hollow tube of sheath material that is configured to be placed over the balloon 114 or other region of a catheter 116, such as in the manner illustrated in FIGs. 3 and 4.
  • the sheath 102 is further configured to be rotatable about the catheter shaft and/or balloon 114, even when a stent 120 has been positioned about and/or affixed to the sheath 102.
  • the sheath 102 may be constructed of a variety of low friction materials such as PTFE, HDPE, etc.
  • the sheath 102 is at least partially constructed of a hydrophilic material, such as hydrophilic polymers such as; TECOPFflLIC ® material available from Thermedics Polymer Products, a division of VIASYS Healthcare of Wilmington, Massachusetts; TECOTHANE ® , also available from Thermedics Polymer Products; hydrophilic polyurethanes, and/or aliphatic, polyether-based thermoplastic hydrophilic polyurethane; and any other material that provides the sheath 102 with the ability to rotate freely about the balloon 114 when in the "wet" state, such as when the catheter is exposed to body fluids during advancement through a vessel.
  • hydrophilic polymers such as; TECOPFflLIC ® material available from Thermedics Polymer Products, a division of VIASYS Healthcare of Wilmington, Massachusetts; TECOTHANE ® , also available from Thermedics Polymer Products; hydrophilic polyurethanes, and/or aliphatic, polyether-based thermoplastic hydrophilic
  • Suitable sheath materials may also provide the sheath with rotatability in the "dry", or pre-insertion, state, but with the application of a greater amount of force than when in the wet state, such materials are referred to herein as being tecophilic.
  • a sheath 102 at least partially constructed from tecophilic material provides the sheath 102 with the ability to rotate freely about the balloon 114 when in the "wet” state, such as when the catheter is exposed to body fluids during advancement through a vessel.
  • the tecophilic sheath 102 is also capable of rotation in the "dry", or pre-insertion, state, but with the application of a greater amount of force than when in the wet state.
  • the sheath 102 maybe constructed of one or multiple materials, in one or more layers.
  • the sheath 102 may comprise an outer layer of a softer material than that of the material used in constructing an inner layer, such as has been previously described.
  • the sheath 102 maybe comprised of a matrix of a first material 111 and have one or more supportive stripes, strands, members or areas of a second supportive material 113 within, external to or internal to such a matrix.
  • the composition of the sheath 102 material, whether a single, multiple layer or stripe reinforced extrusion may include essentially any appropriate polymer or other suitable materials.
  • suitable polymers include Hydrophilic Polyurethanes, Aromatic Polyurethanes, Polycarbonate base Aliphatic Polyurethanes, Engineering polyurethane, Elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX), and Silicones, Polyether-ester (for example a polyether-ester elastomer such as Arnitel available from DSM Engineering Plastics), Polyester (for example a polyester elastomer such as Hytrel available from Du Pont), or linear low density polyethylene (for example Rexell).
  • PEBA polyether block amide
  • Polyether-ester for example a polyether-ester elastomer such as Arnitel available from DSM Engineering Plastics
  • Polyester for example a polyester elastomer such as Hytrel available from Du Pont
  • linear low density polyethylene for example Rexell
  • Example of suitable re-inforcing materials whether alone or blended with other materials, mixtures or combination or copolymers include all Polyamides (for example, Durethan available from Bayer or Cristamid available from ELF Atochem), polyethylene (PE). Marlex high-density polyethylene, polyetheretherketone (PEEK), polyimide (PI), and polyetherirnide (PEI), liquid crystal polymers (LCP), and Acetal (Delrin or Celcon).
  • the inner surface of the sheath 102 or the outer surface of the balloon 114 may include a coating of one or more low friction materials or include one or more low friction materials in its construction. Such a coating 401 is shown in FIG.
  • Coating 401 may however by placed between the balloon 114 and sheath 102 at any time.
  • a suitable coating material include but are not limited to: hydrogel, silicon, and/or BIOSLIDE ® available from SciMed Life Systems, Inc. of Maple Grove Minnesota.
  • the sheath 102 is configured to be freely rotatable about a balloon of a catheter even when a stent 120, such as is shown in FIGs. 2 and 4 is crimped onto the sheath 102.
  • a proximal portion 122 of the stent 120 is also disposed about at least a portion of the secondary guidewire housing 104.
  • Stent 120 may be a stent, such as is shown in FIG. 6, which is at least partially constructed of a plurality of interconnected struts, connectors or members 132.
  • the stent 132 defines a proximal opening 134, a distal opening 136 and a flow path 138 therebetween.
  • the cell openings 130 are in fluid communication with the flow path 138.
  • the members 132 that define the selected cell opening 130a, as well as the shape of the opening 130a through which the secondary guidewire 108 exits the stent may be distorted or modified in order to accommodate the passage of secondary guidewire 108 and/or the secondary guidewire housing 104 therethrough.
  • the modified cell opening 130a hereinafter referred to as secondary opening 130a, is positioned on the stent 120 between the proximal opening 134 and the distal opening 136.
  • FIGs 7 and 8 The manner in which the secondary opening 130a, the members 132 adjacent thereto, and to an extent the stent 120 itself, are modified or distorted by the position of the secondary guidewire and/or secondary guidewire housing is depicted in FIGs 7 and 8. It should be noted that when the stent 120 is placed on the assembly in the manner described above, the distortion of the secondary opening 130a and the adjacent members 132 is of a miijimal extent, and is provide only to allow sliding passage of the secondary guidewire 108, and if desired a distal portion of the secondary guidewire housing 104, through the secondary opening 130a. As such, the actual size of the secondary opening 130a may be substantially similar, or only marginally different than that of the surrounding cell openings 130.
  • stent 120 may be a standard "single vessel" stent that is provided with a secondary opening 130a in the manner described above, the stent 120 may also be a bifurcated stent having a trunk or stem portion, with one or more leg portions and/or branch openings adjacent thereto, through one of which the secondary guidewire may be passed.
  • Such bifurcated stents and stent assemblies are well known in the art.
  • the stent 120, or one or more portions thereof may be configured to deliver one or more therapeutic agents to a delivery site such as within the vessel 199 or one or more areas adjacent thereto, such as shown in FIGs. 5 and 9.
  • one or stent members 132 may be configured to include one or more holes, notches, or other surface features to which one or more therapeutic agents 400 may be placed for delivery to the aneurysm site.
  • a therapeutic agent may be placed on the stent in the form of a coating, hi at least one embodiment the coating includes at least one therapeutic agent and at least one polymer.
  • a therapeutic agent may be a drug, a non-genetic agent, a genetic agent, etc.
  • non-genetic therapeutic agents include but a re not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethyllcetone); anti-proliferative agents such as enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5- fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors;
  • an agent may include but is not limited to: anti-sense DNA and RNA; DNA coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules; angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transfonning growth factor ⁇ and ⁇ , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor ⁇ , hepatocyte growth factor and insulin like growth factor; cell cycle inhibitors including CD inhibitors, thymidine kinase ("TK”) and other agents useful for interfering with cell proliferation; at least one of the family of bone morphogenic proteins (“BMP's”) such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP- 10, BMP-11, BMP-12, BMP's
  • BMP's bone morph
  • cellular material may include but is not limited to: cells of human origin (autologous or allogeneic); cells of non- human origin (xenogeneic) and any combination thereof.
  • cellular material include but are not limited to the following:
  • SP - side population cells
  • SP cells are thought to be some of the most primitive adult stem cells. They are isolated by a specific FACS technique utilizing the ability of SP cells to exclude Hoechst dye from the nucleus.
  • SP cells have been isolated from most tissues, including: cardiac and skeletal muscle. By the more common surface protein identification these cells are Lin, Sca-1 + , c-Kit + , CD43 + , CD45 + , CD34 " Lin " - (lineage negative cells) This group of cells is isolated from the bone marrow and all cells which have differentiated to a specific lineage (e.g. red blood cells) have been removed. Therefore leaving all of the stem and progenitor cells.
  • a specific lineage e.g. red blood cells
  • LincKit "1" - cKit is the cell surface receptor for stem cell factor, and therefore a logical choice for stem cell selection.
  • MSC mesenchymal stem cells
  • mesenchymal tissues e.g. bone, cartilage, fat
  • cardiomyocytes e.g. cardiomyocytes under certain conditions.
  • a subpopulation of MSCs has been shown to self-renew faster and have a greater potential for multipotential differentiation than the general MSC population.
  • D. Prockop from Tulane U. is publishing in this area.
  • Cord Blood Cells Derived from the blood remaining in the umbilical vein following child birth. This blood has been shown to contain a higher percentage of immature stem cells or progenitor cells. Typically, a matched donor must be found for patients, but a lower incidence of graft versus host disease compared to stem cell isolation from adult blood has been reported. Disadvantages include: insufficient cell number in small blood volumes, unforeseen congenital defects, and contamination by mother's blood which is likely not HLA matched. Cardiac or other tissue derived stem cells - Most work to date has focused on isolating stem cells from bone marrow. This is due to extensive work in improving bone marrow transplants for chemotherapy and leukemia treatments.
  • stem cells which can be identified by similar means (e.g. SP, cKit) can be isolated from other tissues (e.g. fat, cardiac muscle).
  • Whole bone marrow - An "it's in there" approach where whole bone marrow (filtered for bone particles) is transplanted. Benefits include: little processing, all stem and progenitor cells are present, and matrix proteins and growth factors may also be present. Downside - if one or two stem cell types are responsible for cardiac improvement they will only be present in very low numbers.
  • BM-MNCs - bone marrow mononuclear cells
  • EPCs - endothelial progenitor cells Isolated from bone marrow based on cell surface markers, these cells will become endothelial cells. In theory, these cells will form new blood vessels when delivered to ischemic tissue.
  • Skeletal myoblasts - or satellite cells
  • These cells are responsible for the regeneration of skeletal muscle following injury. They have the ability to fuse with other myoblasts or damaged muscle fibers.
  • MDCs - muscle derived cells
  • MDCs - muscle derived cells
  • the isolation technique preplating entails collecting cells which attach to culture dishes at different times after biopsy. Cells with the best potential plate in the 6 th group and takes several days to obtain. Investigators working with these cells claim they are a refined population of myoblasts and should result in higher engraftment efficiencies and efficacious procedures.
  • Endothelial cells Transplantation of autologous endothelial cells along with a fibrin matrix induced angiogenesis and improved cardiac function in an ischemic sheep model.
  • Adult cardiomyocytes
  • Fibroblasts - Easily obtained from adult tissues, fibroblasts may provide growth factors or participate in the would healing response. Fibroblast play a critical role in wound healing; the synthesis and deposition of extracellular matrix. Fibroblasts commonly become contractile in wound healing environments. Smooth muscle cells - Isolated from arteries, these cells may participate or encourage angiogenesis and/or beneficial cardiac remodeling following MI. MSCs + 5-aza - Culture of mesenchymal stem cells with 5-aza forces differentiation into cardiomyocytes. These cells beat spontaneously after treatment.
  • Adult cardiac fibroblasts + 5-aza - In theory, in vitro treatment of cardiac fibroblasts with 5- aza will result in differentiation into myogenic cells.
  • Tissue engineered grafts Isolation of cells from the patient which are then seeded onto and cultured within resorbable scaffolds (e.g. collagen, PLGA). These cell seeded constructs are then implanted into the patient.
  • MyoD scar fibroblasts - MyoD family of transcription factors prompt skeletal muscle cell differentiation in fibroblasts. Procedure involves isolation of cardiac scar fibroblasts, genetic transfection with MyoD in vitro and delivery of the cells to the heart to encourage myogenesis.
  • Pacing cells - Genetically modified fibroblasts which become electrically conducting and signal generators.
  • Embryonic stem ceU clones Use of cloning technology to produce cardiomyocytes, progenitors, or stem ceUs which are geneticaUy identical to the patient.
  • Embryonic stem ceUs These ceUs are the most primitive of ceUs and wiU differentiate into functional cardiomyocytes under certain conditions. Both political and technological hurdles must be overcome before commercialization of this technology.
  • ceUs Fetal or neonatal ceUs - Isolated from the heart of donors, these ceUs may incorporate into host tissue without immune rejection. Some cardiomyocyte progenitor ceUs must be present due to the continued growth of the heart in fetal and neonatal humans.
  • Tissue engineered grafts - Isolation of ceUs from a donor which are then seeded onto and cultured within resorbable scaffolds (e.g. coUagen, PLGA). These ceU seeded constructs are then implanted into the host or recipient.
  • resorbable scaffolds e.g. coUagen, PLGA.
  • These ceU seeded constructs are then implanted into the host or recipient.
  • the modified ceUs will then be transplanted into the host or patient.
  • Teratoma derived ceUs - A teratocarcinoma is a form of cancer in which the tumor is composed of a heterogeneous mixture of tissues. Through isolation of ceUs from this tumor and in vitro manipulation and culture a neuronal ceU line has been developed. Layton Biosciences has successfuUy used these ceUs to form new brain tissue in stroke patients. SimUar techniques may be used to produce a myogenic ceU line.
  • a therapeutic agent comprises at least one polymer agent or coating
  • the at least one coating may include but is not limited to: polycarboxyUc acids; ceUulosic polymers, including ceUulose acetate and ceUulose nitrate; gelatin; polyvinylpyrroUdone; cross-linked polyvinylpyrroUdone; polyanhydrides including maleic anhydride polymers; polyamides; polyvinyl alcohols; copolymers of vinyl monomers such as EVA; polyvinyl ethers; polyvinyl aromatics; polyethylene oxides; glycosaminoglycans; polysaccharides; polyesters including polyethylene terephthalate; polyacrylamides; polyethers; polyether sulfone; polycarbonate; polyaUcylenes including polypropylene, polyethylene and high molecular weight polyethylene; halogenated polyaUcylenes including polytetrafluoroethylene; polyurethanes; polyorthoesters;
  • an example of a suitable polymer agent or coating comprises block copolymers comprising at least one A block and at least one B block.
  • the A blocks are preferably soft elastomeric blocks, which are based upon one or more polyolefins, or other polymer with a glass transition temperature at or below room temperature.
  • the A blocks can be polyolefihic blocks having alternating quaternary and secondary carbons of the general formulation: -(CRR'-CH 2 ) n -, where R and R are, independently, linear or branched aUphatic groups such as methyl, ethyl, propyl, isopropyL butyl, isobutyl and so forth, or represent cycUc aUphatic groups such as cyclohexane, cyclopentane, and the Uke, either with or without pendant groups.
  • a blocks include siUcone rubber blocks and acrylate rubber blocks.
  • the B blocks are preferably hard thermoplastic blocks with glass transition temperatures significantly higher than the elastomeric A blocks which, when combined with the soft A blocks, are capable of, inter alia, altering or adjusting the hardness of the resulting copolymer to achieve a desired combination of quaUties.
  • B blocks include polymers of methacrylates or polymers of vinyl aromatics. More specific examples
  • styrene derivatives e.g., ⁇ -methylstyrene, ring-aUcylated styrenes or ring-halogenated styrenes or other substituted styrenes where one or more
  • the block copolymers are provided in a variety of architectures, including cycUc, linear, and branched architectures.
  • Branched architectures include star-shaped architectures (e.g., architectures in which three or more chains emanate from a single region), comb architectures (e.g., copolymers having a main chain and a pluraUty of side chains), and dendritic architectures (including arborescent or hyperbranched copolymers).
  • Some specific examples of such block copolymers include the foUowing: (a) BA
  • linear diblock (linear diblock), (b) BAB or ABA (linear triblock), (c) B(AB) n or A(BA) n (linear alternating block), or (d) X-(AB) doctrine or X-(BA) arise (includes diblock, triblock and other radial block copolymers), where n is a positive whole number and X is a starting seed, or initiator, molecule.
  • block polymers include branched block copolymers such as dendritic block copolymers, wherein at least one of the A and B blocks is branched, for instance, where the A blocks are branched and are capped by the B blocks.
  • the collar 150 is engaged to the proximal portion 140 of the secondary guidewire housing 104 by any engagement mechanism desired, such as welding, bonding, mechanical engagement, adhesive engagement, etc.
  • the proximal portion 140 of the secondary guidewire housing 104 and the coUar 150 are engaged externaUy at engagement site 142.
  • the secondary guidewire housing 104 may be passed at least partiaUy through the coUar 150, and/or the coUar 150 may define a lumen through which the secondary guidewire 108 may be passed before entering into the secondary guidewire housing 104.
  • CoUar 150 maybe a substantially cylindrical member that is disposed about the shaft 144 of the catheter 116 at a position proximal of the baUoon 114.
  • the coUar 150 maybe characterized as defining a catheter shaft lumen 146 through which the catheter shaft 144 is passed.
  • the collar 150 defines a catheter shaft lumen 146 which has a diameter greater than the outer diameter of the shaft 144.
  • one or more lubricious substances may be placed between the coUar 150 and the shaft 144 to further encourage free rotation therebetween. While the rotating coUar 150 is free to rotate about the shaft 144, in some embodiments it will also be capable of being longitudinaUy displaced along the shaft 144 as weU.
  • one or more locks or hubs 152 may be affixed about the shaft 144 on one or both sides of the coUar 150 to prevent or limit the potential longitudinal displacement of the coUar 150 relative to the shaft 144.
  • the combined system 300 is ready for use in a stent deUvery procedure.
  • the stent deUvery system 300 includes a pair of retaining and/or protective sleeves 170 and 172.
  • the sleeves maybe constructed from any of a variety of materials such as are described in U.S. 6,443,980; U.S. 6,221,097; U.S. 6,554,841; U.S. Pub. App. No. 2002-0038140 Al; and U.S. Pub. App. No. 2002-0038141 Al, the entire content of each of which are incorporated herein by reference, but are typicaUy constructed of one or more polymeric and/or elastomeric materials.
  • Sleeves 170 and 172 may function to retain the ends of the baUoon 114 in a reduced state prior to deUvery and/or to aid in deflation and coUapse of the baUoon 114 foUowing deUvery of the stent by providing a radiaUy inward acting force on the ends of the baUoon 114.
  • the sleeves 170 and 172 may be provided with a sufficient length to aUow a first portion 178 of each sleeve to be disposed over a respective proximal end portion 174 and/or distal end portion 176 of the stent 120.
  • each sleeve 170 and 172 the increased diameter of the baUoon 114 and/or stent 120 cause the first portion 178 of each sleeve 170 and 172 to be retract or be puUed off of the end portions 174 and 176 of the stent 120, thereby freeing the stent for deUvery from the system 300.
  • sleeves 170 and 172 aid in retaining the stent and/or baUoon in an unexpanded or pre-deUvery state
  • the each sleeve is also rotatable about the catheter shaft 144, in a manner similar to that of the sheath 102.
  • a second portion of each sleeve corresponding to the portion of the sleeve engaged to the catheter shaft 144, comprises a rigid reinforcing member 179 that is rotatably engaged about the catheter shaft 144.
  • the rigid reinforcing member 179 may be constructed out of any material or materials having a higher durometer value than that of the material or materials from which the retaining or first portion 178 is constructed.
  • the sleeves 170 and 172 wiU have a hybrid construction of at least two materials having different hardnesses. In some embodiments it may be desirable to provide only the distal end of the system 300 with a sleeve 172.
  • the proximal sleeve includes an opening 171, such as is best depicted in FIGs. 11 and 12, to accommodate passage of the secondary guidewire housing 104 therethrough.
  • the proximal sleeve 170 may be drawn proximaUy along the secondary guidewire housing 104 and off of the proximal end portion 174 off the stent 120.
  • at least a portion of the inside surface 173 of one or both sleeves may be at least partiaUy coated with a lubricious substance.
  • the baUoon 114 is sufficiently folded or otherwise maintained in the unexpanded configuration, such that providing a sleeve or other protective/retaining means over the ends of the baUoon is unnecessary and/or undesirable.
  • the rotatable sheath 102 includes one or two end portions 180 and 182, which extend beyond the corresponding end portions 174 and 176 of the stent 120.
  • the end portions 180 and 182 comprise flaps 181 and 183, which are configured to be folded or roUed back over the corresponding end portion 174 and 176 of the stent 120, while in the stent is in the unexpanded or pre-deUvery state.
  • a proximal flap 181 may have any of a variety of configurations to provide at least partial coverage of the proximal end portion 174 of the stent 120 in the unexpanded state.
  • a proximal flap 181 is provided with a tapered shape which aUows the flap to be folded back with an angled configuration to a provide the proximal end portion 174 of the stent 120 with complete or nearly complete coverage in the region opposite from the secondary guidewire housing 104.
  • the flap 181 As the folded flap 181 approaches the region of the secondary guidewire housing 104 the coverage of the proximal end portion of the stent 120 by the flap 181 is reduced in the tapering manner shown.
  • the flaps 181 and 183 maybe configured to exert an inwardly acting radial force upon the ends of the baUoon 114 foUowing deUvery of the stent 120, in order to encourage the baUoon to refold or fully coUapse for withdrawal from the body.
  • the proximal flap 181 may define a slot or opening 184, such as is shown in FIGs 16 and 17. Slot 184 aUows the flap 180 to be folded back over the proximal end portion 174 of the stent 120 to provide a unifonn length of coverage to the stent, excepting the region of the stent 120 wherein the secondary guidewire housing 104 is positioned.
  • At least a portion of the stent side surface of the flaps 181 and 183 and/or the corresponding end portions 174 and 176 of the stent 120 may include a lubricious coating thereon to encourage the sUding retraction of the flaps from the stent during expansion.
  • the sheath 102 may be configured to have end portions 180 and 182 which can be folded back over the corresponding end portions 174 and 176 of the stent 120, in some embodiments, an example of which is shown in FIGs.
  • the end portions 180 and 182 of the sheath define hub regions 185 and 187 which have a greater outside diameter than the stent mounting region 189 of the sheath positioned therebetween.
  • the outer diameter of a distal hub 187 is equal to or greater than the outer diameter of the distal end portion 176 of the stent 120 in the unexpanded state.
  • a proximal hub 185 is also included. In some embodiments, such as those shown in FIGs.
  • the proximal hub 185 underUes or is adjacent to the secondary guidewire housing 104.
  • This configuration provides the proximal hub 185 with a shape wherein only a "bottom" portion 191 of the proximal hub 185 has an outer diameter greater than that of the stent 120 and a "top” portion 193 of the hub 185 being adjacent to the secondary guidewire housing 104.
  • the secondary guidewire housing 104 maybe bonded, adhered, fused or otherwise engaged to the proximal hub 185.
  • the secondary guidewire housing 104 may be utilized to protect the area of the proximal end portion 174 of the stent not protected by the top portion of the hub 185.
  • the secondary guidewire housing 104 may include a bent portion 197 which bends around the proximal hub 185 of the sheath 102 prior to passage through the stent 120.
  • This bent portion 197 effectively adds its diameter to that of the proximal hub 185, such that the bent portion 197 extends radiaUy outward to a greater extent than the proximal end portion 174 of the stent 120.
  • the proximal end portion 174 of the stent 120 is uniformly protected by the combination of the hub 185 and bent portion 197 of the secondary guidewire housing 104.
  • the proximal hub 185 defines an opening 221, through which the secondary guidewire housing 104 passes.
  • the proximal hub 185 may be shaped and sized to have a diameter that is uniformly larger, or at least equal to, the diameter to the proximal end portion 174 of the stent 120 in the unexpanded state.
  • the secondary guidewire housing 104 maybe configured to provide the proximal end 174 of the stent 120 with improved edge protection and/or coverage. For example, in the embodiment shown in FIG.
  • the hypotube 64 encloses the inner shaft 103 in an asymmetrical relationship, such as is depicted in the cross- sectional view of FIG. 22.
  • the hypotube 64 maybe tapered or provided with a stepped configuration where it enters under the proximal end portion 174 of the stent 120.
  • proximal to the stent 120 is displaced relative to the stent 120, such that a proximal portion 223 of the hypotube 64 extends radiaUy outward from the system to an extent equal to or greater than the adjacent region of the proximal end portion 174 of the stent 120.
  • a distal portion 225 of the hypotube 64 which extends from the proximal portion 223 tapers or steps down to a reduced diameter portion which extends through the secondary opening 130a of the stent 120.
  • one or both cones 190 and 192 of the baUoon 114 may have a "puffed" configuration, such that in the unexpanded state, at least a portion of one or both cones 190 and 192 have a diameter greater than the outside diameter of the sheath 102 and/or stent 120 mounted on the baUoon 114, such as is shown in FIG. 24.
  • the cones In the expanded state, shown in FIG. 26, the cones have a diameter less than that of the stent 120.
  • the distal cone 192 is provided with a puffed configuration.
  • one or both puffed cones are configured such that they do not interfere with the rotatabiUty of the sheath 102 about the baUoon 114 when in the unexpanded state. It wiU be recognized that the cones 190 and 192 of a baUoon 116 may be provided with the puffed configuration shown in a variety of ways.
  • foUowing assembly of the system 300 fluid may be evacuated from the baUoon 114 while one or both cones 190 and 192 are exposed to vacuum, thereby aUowing the baUoon 114 to attain its folded pre- deUvery configuration whUe simultaneously causing the cones to be distorted or shaped into the puffed configuration shown in FIG. 24.
  • the portion of the baUoon 114 that underUes the sheath 102 may be externaUy retained in the unexpanded state, whUe fluid is injected into the baUoon 116 causing the cones to expand.
  • the cones may be expanded to a degree sufficient to distort the cones 190 and 192 into the puffed configuration shown. It is recognized that other methods of providing one or both cones 190 and 192 with the puffed configuration shown in FIG. 24 and 25 and such methods are within the scope of the invention.
  • the invention has been described with reference to the embodiments.
  • any dependent claim which foUows should be taken as alternatively written in a multiple dependent form from aU prior claims which possess aU antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from aU previous claims).
  • the foUowing dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim Usted in such dependent claim below.

Abstract

A catheter assembly (100) comprises a catheter (116), a rotatable sheath (102), a guidewire housing (104) and a stent (120). The rotatable sheath is disposed about at least a portion of the catheter shaft (144) and is rotatable thereabout. The stent is disposed about a stent receiving region of the rotatable sheath and at least a portion of the guidewire housing. The first end of the rotatable sheath extends beyond a proximal end region of the stent and the second end region of the rotatable sheath extends beyond a distal end region of the stent.

Description

Rotating Balloon Expandable Sheath Bifurcation Delivery System
CROSS-REFERENCE TO RELATED APPLICATIONS Not Applicable
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH Not Applicable
BACKGROUND OF THE INVENTION Description of the Related Art Catheter systems such as angioplasty catheters, and stent delivery systems, as well as the stents associated therewith, are widely used in the treatment of stenoses, aneurysms, lesions, and other abnormalities within blood vessels and other body lumens. Intravascular stents are used in coronary, renal, and carotid arteries, for example, to maintain an open passage through the artery. In patients whose coronary heart disease consists of focal lesions, stents have proven effective. For example, where only a single coronary artery is clogged or where there are short blockages in more than a single artery, stents have been used with a great amount of success. An intravascular stent may be positioned in a clogged artery by a catheter and is often set in place by inflating a balloon upon which the stent is mounted. This expands the diameter of the stent and opens the previously clogged artery. The balloon is then deflated and removed from the patient while the stent retains an open passage through the artery. Treatment at bifurcation sites has been difficult. Although efforts have been made to use a stent at bifurcations, these sites have previously been problematic to treat. The specialty stents designed for bifurcations generally need specific alignment, radially as well as longitudinally. For example, U.S. Patent No. 5,749,825 is representative of a catheter system that is intended to treat stenoses at an arterial bifurcation. The disclosure of 5,749,825 is hereby incorporated by reference. A stent delivery system employing a stent assembly with branches intended for deployment in the adjacent branches of a vessel bifurcation has been proposed to allow placement of a portion of the assembly in both a primary passage, such as an artery, and a secondary passage, such as a side branch artery. Additionally, these stents generally have an opening which allows for unimpeded blood flow into the side branch artery. However, problems are still encountered in orienting the stent relative to the side branch at the bifurcation of the primary and secondary passages. Moreover, such bifurcated assemblies are typically specially manufactured at an increased cost over a more standard stent intended for single vessel deployment. In delivering a stent to a vessel location, many current devices rely on either passive torque (e.g., pushing the stent forward and allowing the stent that is fixed on the guidewire/balloon to passively rotate itself into place) or creating torque from outside of the patient to properly orient the medical device in the passage. These devices and methods of achieving proper angular orientation have not been shown to be effective in properly placing and positioning the stent. In addition, many catheter systems which are currently utilized to deploy a stent or other implantable device into a body lumen do not provide adequate stent edge protection prior to delivery. Thus, a need exists to provide a catheter which is capable of allowing a medical device such as a stent to be easily maneuvered and aligned at a vessel bifurcation or other location, while also adequately protecting the edges of the stent during advancement of the catheter through the tortuous confines of a body lumen. All US patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety. Without limiting the scope of the invention a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below. A brief abstract of the technical disclosure in the specification is provided as well only for the purposes of complying with 37 C.F.R. 1.72. The abstract is not intended to be used for interpreting the scope of the claims. BRIEF SUMMARY OF THE INVENTION Some embodiments of the present invention include a freely rotating deployment assembly for a stent assembly for maintaining side branch access and protection. At least one embodiment of the invention includes a medical device with a balloon catheter shaft and a rotating sheath such as is described in U.S. Patent Application No. 10/375,689, filed February 27, 2003 and U.S. Patent Application No. 10/657,472, filed September 8, 2003 both of which are entitled Rotating Balloon Expandable Sheath Bifurcation Delivery, the entire content of both being incorporated herein by reference, wherein the ends of the sheath and/or stent are provided with one or more protective elements. In at least one embodiment the sheath has one or more end regions and an intermediate region, wherein the intermediate region has an outer diameter less than that of either or both end regions. In some embodiments the intermediate region defines a stent mounting region wherein the stent is disposed prior to delivery between end regions of the sheath. In some embodiments prior to expansion one or both cones of the balloon have a diameter that is greater than the unexpanded or predeployed diameter of the sheath and/or stent disposed thereon. In at least one embodiment the catheter further comprises one or more end sleeves or socks, wherein each sleeve has a first end engaged to the catheter shaft adjacent to an end of the balloon. In some embodiments the first end of each sleeve is freely rotatable about the catheter shaft. In at least one embodiment, a sleeve has a second end, which prior to deployment of the stent, is disposed about an end of the stent and during deployment of the stent is retracted therefrom to release the stent into a body lumen. In some embodiments prior to deployment of the stent a proximal sleeve is engaged to the proximal end of the stent and a distal sleeve is engaged to a distal end of the stent. In some embodiments a single sleeve is engaged to only one end of the stent prior to deployment. In some embodiments the medical device comprises a secondary guidewire lumen housing, which itself comprises a reinforcing member, such as a polymer tube of PEBAX, peek, polyimide, etc., a braided tube of metal wire or other material, a hypotube, or other device engaged to the sheath and engaged to the collar. In some embodiments an inner member is positioned within the reinforcing member to define the secondary guidewire lumen. In some embodiments the material of the inner member is more flexible than the material of the reinforcing member. In some embodiments the inner member is longer than the reinforcing member and at least one end of the inner member extends beyond at least one end of the reinforcing member. In at least one embodiment the inner member is concentrically disposed within the reinforcing member. In some embodiments the inner member is asymmetrically disposed within the reinforcing member. In at least one embodiment the proximal end of the reinforcing member is proximally adjacent to the stent. In some embodiments the proximal end of the reinforcing member is tapered. In at least one embodiment the reinforcing member is positioned such that at least a portion of the reinforcing member is radially offset from the distal end of the stent. In at least one embodiment the rotatable sheath has a length longer than the stent. In some embodiments one or both ends of the sheath are folded back over the corresponding ends of the stent prior to delivery. When the stent is deployed the one or both ends of the sheath slidingly retract off of the stent, thereby freeing the ends of the stent for deployment. In some embodiments only the distal end of the sheath is folded over the distal end of the stent prior to delivery. In at least one embodiment the proximal end of the sheath defines a proximal slit or is tapered to accommodate the position of the secondary guidewire lumen housing, such that the proximal end of the sheath may be folded over at least a portion of the proximal end of the stent prior to delivery. These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof. However, for a better understanding of the invention, its advantages and objectives obtained by its use, reference should be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there is illustrated and described a embodiments of the invention.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWTNG(S) A detailed description of the invention is hereafter described with specific reference being made to the drawings. FIG. 1 is a side view of an embodiment of the invention, comprising a rotating sheath assembly. FIG. 2 is a side view of the embodiment shown in FIG. 1 shown configured for delivery of a stent. FIG. 3 is a side view of an embodiment of the invention comprising a catheter assembly. The catheter assembly is provided with a rotating collar. FIG. 4 is a side view of the catheter assembly of FIG. 3 and further comprising the rotating sheath assembly and stent of FIG. 2. FIG. 5 is a side view of an embodiment of the invention wherein the catheter assembly of FIG. 4 is shown being advanced along a guidewire to a vessel bifurcation prior to delivery of the stent. FIG. 6 is a side perspective view of an embodiment of the invention comprising a stent, such as that shown in FIG. 2. FIG. 7 is a side perspective view of the stent shown in FIG. 6 wherein a side branch opening is shown formed from the enlargement of a cell opening in the stent wall. FIG. 8 is a cross-sectional view of the stent of FIG. 7. FIG. 9 is a side view of the stent depicted in FIG. 5, wherein the stent has been delivered from the catheter assembly, by balloon expansion and the assembly subsequently withdrawn from the vessel(s). FIG. 10 is a side view of an embodiment of the embodiment of the invention shown in FIG. 4 which includes protective sleeves. FIG. 11 is a cross-sectional view of a portion of the system shown in FIG. 10 corresponding to section A. FIG. 12 is a cross-sectional view of a portion of the system shown in FIG. 10 corresponding to section B. FIG. 13 is a side view of the embodiment shown in FIG. 10 wherein the sleeves have been retracted from the ends of the stent. FIG. 14 is a side view of an embodiment of the invention wherein each end of the rotating sheath is folded over the corresponding end of the stent. FIG. 15 is a side view of the embodiment shown in FIG. 14, wherein the ends of the sheath have been retracted off of the stent. FIG. 16 is a side view of an embodiment of the invention wherein each end of the rotating sheath is folded over the corresponding end of the stent and the proximal end of the sheath defines a slot. ) FIG. 17 is a side view of the embodiment shown in FIG. 16, wherein the ends of the sheath have been retracted off of the stent. FIG. 18 is a side view of an embodiment of the invention wherein the rotating sheath comprises a pair raised end portions or hubs. FIG. 19 is a side view of an embodiment of the invention shown in FIG. 18 wherein the secondary guidewire housing comprises a bent portion over the proximal hub of the rotating sheath. FIG. 20 is a side view of an embodiment of the invention wherein the rotating sheath comprises a pair raised end portions or hubs, wherein the proximal hub defines a passage for the secondary guidewire housing. FIG. 21 is a side view of an embodiment of the invention wherein the secondary guidewire housing is radially offset from the proximal end of the stent. FIG. 22 is a cross-sectional view of a portion of the system shown in FIG. 21 corresponding to section C. FIG. 23 is a side view of an embodiment of the invention wherein the secondary guidewire housing comprises a step which is radially offset from the proximal end of the stent. FIG. 24 is a side view of an embodiment of the invention wherein the cones of the balloon are provided with a puffed configuration in the unexpanded state. FIG. 25 is a side view of an embodiment of the invention wherein only the distal cone of the balloon is provided with a puffed configuration in the unexpanded state. FIG. 26 is a side view of either of the embodiments shown in FIGs. 24 and 25, wherein the balloon is shown in an expanded state.
DETAILED DESCRIPTION OF THE INVENTION While this invention may be embodied in many different forms, there are described in detail herein specific embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated. For the purposes of this disclosure, Mice reference numerals in the figures shall refer to like features unless otherwise indicated. Referring now to the drawings which are for the purposes of illustrating embodiments of the invention only and not for purposes of limiting same, in at least one embodiment of the invention, an example of which is shown in FIG. 1 a rotating sheath assembly 100 is shown which comprises a tubular sleeve or sheath 102 and a positioning or secondary guidewire housing 104. The housing 104 defines a secondary guidewire lumen 106 through which a secondary guidewire 108 may be passed. Though the housing 104 maybe constructed of a wide variety of materials including metal plastic, etc., in at least one embodiment the housing 104 is an external reinforcing member or hypotube 64. The hypotube 64 may comprise stainless steel, one or more polymer materials or other material. In some embodiments the housing 104 is provided with one or more openings 110 along its length. In at least one embodiment the housing 104 is spiral cut to provide at least a continuous opening 110 which acts to provide improve the flexibility of the housing 104. In at least one embodiment the secondary guidewire housing 104 further comprises an inner shaft 103, about which the hypotube 64 is disposed. In at least one embodiment the inner shaft 103 is a flexible hollow tubular member which extends distally beyond the distal end of the hypotube 64. This distal and/or proximal tips 105 of the inner shaft 103 provides the housing with a flexible protective sheath about the guidewire 108 as it passes out of the secondary guidewire lumen 106. Such a protective covering prevents the guidewire 108 from excessively rubbing against the wall 201 of the vessel 199, such as in the manner depicted in FIG. 5; even where the secondary guidewire 108 exits the secondary lumen 106 at a significant angle. The inner shaft 103 may be constructed of any of a variety of flexible materials such as: PEBAX, nylon, urethane, and/or other materials in a single layer, multi-layer and/or braided configuration. In some embodiments the shaft 144 of the catheter 116 defines a primary guidewire housing 211 through which a primary guidewire 107 may be advanced. In uses guidewires 107 and 108 are passed through a lumen or other body vessel 209 to a bifurcation 203. Primary guidewire 107 is then advanced into a primary branch of passage 205 of the bifurcation 203 while the secondary guidewire 108 is advanced into the adjacent or secondary branch 207 of the bifurcation 203. As the system is advanced along both guidewires 107 and
108, as a result of the divergent paths defined by the guidewires 107 and 108, the rotatable sleeve 104 will rotate the stent 120 into a desired position so that the secondary opening 130a of the stent is aligned with the secondary passage 207. In at least one embodiment, the system 300 is a fixed wire system, and as such the use of the prinary guidewire is unnecessary. In some embodiments at least a distal portion of the housing 104 is engaged to at / least a proximal portion of the sheath 102 at an engagement site 112. The manner or mechanism of engagement between the sheath and housing 104 may be by bonding, welding, adhering adhesively engaging, mechanically engaging or otherwise connecting the surfaces of the respective sheath 102 and housing 104. The sheath 102 is a hollow tube of sheath material that is configured to be placed over the balloon 114 or other region of a catheter 116, such as in the manner illustrated in FIGs. 3 and 4. The sheath 102 is further configured to be rotatable about the catheter shaft and/or balloon 114, even when a stent 120 has been positioned about and/or affixed to the sheath 102. In order to ensure that the sheath 102 is rotatable about a balloon 114, even with a stent 120 crimped on to the sheath 102 and the catheter is being advanced through the a body, the sheath 102 may be constructed of a variety of low friction materials such as PTFE, HDPE, etc. In at least one embodiment the sheath 102 is at least partially constructed of a hydrophilic material, such as hydrophilic polymers such as; TECOPFflLIC® material available from Thermedics Polymer Products, a division of VIASYS Healthcare of Wilmington, Massachusetts; TECOTHANE®, also available from Thermedics Polymer Products; hydrophilic polyurethanes, and/or aliphatic, polyether-based thermoplastic hydrophilic polyurethane; and any other material that provides the sheath 102 with the ability to rotate freely about the balloon 114 when in the "wet" state, such as when the catheter is exposed to body fluids during advancement through a vessel. Suitable sheath materials may also provide the sheath with rotatability in the "dry", or pre-insertion, state, but with the application of a greater amount of force than when in the wet state, such materials are referred to herein as being tecophilic. A sheath 102 at least partially constructed from tecophilic material provides the sheath 102 with the ability to rotate freely about the balloon 114 when in the "wet" state, such as when the catheter is exposed to body fluids during advancement through a vessel. The tecophilic sheath 102 is also capable of rotation in the "dry", or pre-insertion, state, but with the application of a greater amount of force than when in the wet state. In some embodiments the sheath 102 maybe constructed of one or multiple materials, in one or more layers. For example, the sheath 102 may comprise an outer layer of a softer material than that of the material used in constructing an inner layer, such as has been previously described. In some embodiments, an example of which is shown in FIG. 1 , the sheath 102 maybe comprised of a matrix of a first material 111 and have one or more supportive stripes, strands, members or areas of a second supportive material 113 within, external to or internal to such a matrix. The composition of the sheath 102 material, whether a single, multiple layer or stripe reinforced extrusion may include essentially any appropriate polymer or other suitable materials. Some example of suitable polymers include Hydrophilic Polyurethanes, Aromatic Polyurethanes, Polycarbonate base Aliphatic Polyurethanes, Engineering polyurethane, Elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX), and Silicones, Polyether-ester (for example a polyether-ester elastomer such as Arnitel available from DSM Engineering Plastics), Polyester (for example a polyester elastomer such as Hytrel available from Du Pont), or linear low density polyethylene (for example Rexell). Example of suitable re-inforcing materials whether alone or blended with other materials, mixtures or combination or copolymers include all Polyamides (for example, Durethan available from Bayer or Cristamid available from ELF Atochem), polyethylene (PE). Marlex high-density polyethylene, polyetheretherketone (PEEK), polyimide (PI), and polyetherirnide (PEI), liquid crystal polymers (LCP), and Acetal (Delrin or Celcon). In some embodiments the inner surface of the sheath 102 or the outer surface of the balloon 114 may include a coating of one or more low friction materials or include one or more low friction materials in its construction. Such a coating 401 is shown in FIG. 3, as being depicted on the surface of the balloon 114 before assembly 100 has been placed thereabout, such as is depicted in FIG. 4. Coating 401 may however by placed between the balloon 114 and sheath 102 at any time. Some examples of a suitable coating material include but are not limited to: hydrogel, silicon, and/or BIOSLIDE® available from SciMed Life Systems, Inc. of Maple Grove Minnesota. As mentioned above, the sheath 102 is configured to be freely rotatable about a balloon of a catheter even when a stent 120, such as is shown in FIGs. 2 and 4 is crimped onto the sheath 102. When properly positioned on the sheath 102, a proximal portion 122 of the stent 120 is also disposed about at least a portion of the secondary guidewire housing 104. When properly positioned about the sheath 102 and the housing 104, at least a portion of the housing 104 and/or the secondary guidewire 108 extends distally through a cell opening 130 of the stent 120. Stent 120 may be a stent, such as is shown in FIG. 6, which is at least partially constructed of a plurality of interconnected struts, connectors or members 132. The stent 132 defines a proximal opening 134, a distal opening 136 and a flow path 138 therebetween. The cell openings 130 are in fluid communication with the flow path 138. When the secondary guidewire 108 and/or the secondary guidewire housing 104 is threaded through one of the cell openings 130 when the stent is positioned onto the assembly 100, such as is shown in FIGs. 2 and 4, the members 132 that define the selected cell opening 130a, as well as the shape of the opening 130a through which the secondary guidewire 108 exits the stent, may be distorted or modified in order to accommodate the passage of secondary guidewire 108 and/or the secondary guidewire housing 104 therethrough. The modified cell opening 130a, hereinafter referred to as secondary opening 130a, is positioned on the stent 120 between the proximal opening 134 and the distal opening 136. The manner in which the secondary opening 130a, the members 132 adjacent thereto, and to an extent the stent 120 itself, are modified or distorted by the position of the secondary guidewire and/or secondary guidewire housing is depicted in FIGs 7 and 8. It should be noted that when the stent 120 is placed on the assembly in the manner described above, the distortion of the secondary opening 130a and the adjacent members 132 is of a miijimal extent, and is provide only to allow sliding passage of the secondary guidewire 108, and if desired a distal portion of the secondary guidewire housing 104, through the secondary opening 130a. As such, the actual size of the secondary opening 130a may be substantially similar, or only marginally different than that of the surrounding cell openings 130. It should also be further noted that while stent 120 may be a standard "single vessel" stent that is provided with a secondary opening 130a in the manner described above, the stent 120 may also be a bifurcated stent having a trunk or stem portion, with one or more leg portions and/or branch openings adjacent thereto, through one of which the secondary guidewire may be passed. Such bifurcated stents and stent assemblies are well known in the art. In at least one embodiment the stent 120, or one or more portions thereof, may be configured to deliver one or more therapeutic agents to a delivery site such as within the vessel 199 or one or more areas adjacent thereto, such as shown in FIGs. 5 and 9. In some embodiments one or stent members 132, such as is shown in FIG. 6, maybe configured to include one or more holes, notches, or other surface features to which one or more therapeutic agents 400 may be placed for delivery to the aneurysm site. A therapeutic agent may be placed on the stent in the form of a coating, hi at least one embodiment the coating includes at least one therapeutic agent and at least one polymer. A therapeutic agent may be a drug, a non-genetic agent, a genetic agent, etc. ' Some examples of suitable non-genetic therapeutic agents include but a re not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethyllcetone); anti-proliferative agents such as enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5- fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; vascular cell growth promoters such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters, vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, biftmctional molecules consisting of a growth factor and a cytotoxin; bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vascoactive mechanisms, and any combinations thereof. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: anti-sense DNA and RNA; DNA coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules; angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transfonning growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor; cell cycle inhibitors including CD inhibitors, thymidine kinase ("TK") and other agents useful for interfering with cell proliferation; at least one of the family of bone morphogenic proteins ("BMP's") such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP- 10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Any of BMP-2, BMP- 3, BMP-4, BMP-5, BMP-6 and BMP-7; dimeric proteins such as homodimers, heterodimers, or combinations thereof, alone or together with other molecules; molecules capable of inducing an upstream or downstream effect of a BMP such as "hedgehog" proteins, or the DNA's encoding them and any combinations thereof. Where a therapeutic includes cellular material, the cellular material may include but is not limited to: cells of human origin (autologous or allogeneic); cells of non- human origin (xenogeneic) and any combination thereof. Some examples of cellular material include but are not limited to the following:
SP - (side population cells) These cells are thought to be some of the most primitive adult stem cells. They are isolated by a specific FACS technique utilizing the ability of SP cells to exclude Hoechst dye from the nucleus. In addition to bone marrow, SP cells have been isolated from most tissues, including: cardiac and skeletal muscle. By the more common surface protein identification these cells are Lin, Sca-1+, c-Kit+, CD43+, CD45+, CD34" Lin" - (lineage negative cells) This group of cells is isolated from the bone marrow and all cells which have differentiated to a specific lineage (e.g. red blood cells) have been removed. Therefore leaving all of the stem and progenitor cells. This is beneficial because all primitive cells remain, but may reduce efficiency by including irrelevant, primitive cell types. Lin"CD34 - Although CD34+ cells have received much attention, many articles have been published lately which suggest the most primitive bone marrow derived stem cells are CD34" LinCD34+ - Presence of the cell surface protein CD34 has been used to identify hematopoietic stem cells. However, the marker is also present on progenitor cells and white blood cells of various levels of maturity.
LincKit"1" - cKit is the cell surface receptor for stem cell factor, and therefore a logical choice for stem cell selection. Most widely studied from bone marrow sources, but have also been isolated from the heart. MSC - (mesenchymal stem cells) Named so because ordinarily these cells differentiate into cells of mesenchymal tissues (e.g. bone, cartilage, fat), but may also differentiate into cardiomyocytes under certain conditions. Easily isolated from bone marrow and, unlike hematopoietic stem cells, proliferate in vitro. A subpopulation of MSCs has been shown to self-renew faster and have a greater potential for multipotential differentiation than the general MSC population. D. Prockop from Tulane U. is publishing in this area. Cord Blood Cells - Derived from the blood remaining in the umbilical vein following child birth. This blood has been shown to contain a higher percentage of immature stem cells or progenitor cells. Typically, a matched donor must be found for patients, but a lower incidence of graft versus host disease compared to stem cell isolation from adult blood has been reported. Disadvantages include: insufficient cell number in small blood volumes, unforeseen congenital defects, and contamination by mother's blood which is likely not HLA matched. Cardiac or other tissue derived stem cells - Most work to date has focused on isolating stem cells from bone marrow. This is due to extensive work in improving bone marrow transplants for chemotherapy and leukemia treatments. However, there is evidence that similar stem cells which can be identified by similar means (e.g. SP, cKit) can be isolated from other tissues (e.g. fat, cardiac muscle). Whole bone marrow - An "it's in there" approach where whole bone marrow (filtered for bone particles) is transplanted. Benefits include: little processing, all stem and progenitor cells are present, and matrix proteins and growth factors may also be present. Downside - if one or two stem cell types are responsible for cardiac improvement they will only be present in very low numbers. BM-MNCs - (bone marrow mononuclear cells) Separated from whole bone marrow by a density gradient centrifugation procedure, this population contains non-granular white blood cells, progenitor cells, and stem cells. EPCs - (endothelial progenitor cells) Isolated from bone marrow based on cell surface markers, these cells will become endothelial cells. In theory, these cells will form new blood vessels when delivered to ischemic tissue. Skeletal myoblasts - (or satellite cells) These cells are responsible for the regeneration of skeletal muscle following injury. They have the ability to fuse with other myoblasts or damaged muscle fibers. Cardiac muscle therapies assume these cells can integrate into the host tissue and improve tissue properties or functionally participate in contraction. MDCs - (muscle derived cells) A population of cells isolated from adult skeletal muscle which are similar to myoblasts. The isolation technique preplating entails collecting cells which attach to culture dishes at different times after biopsy. Cells with the best potential plate in the 6th group and takes several days to obtain. Investigators working with these cells claim they are a refined population of myoblasts and should result in higher engraftment efficiencies and efficacious procedures. Go cells - Recently isolated from adult skeletal muscle, these non-satellite cells express GATA-4 and, under certain in vitro growth conditions, progress to spontaneously beating cardiomyocyte-like cells.
Endothelial cells - Transplantation of autologous endothelial cells along with a fibrin matrix induced angiogenesis and improved cardiac function in an ischemic sheep model. Adult cardiomyocytes
Fibroblasts - Easily obtained from adult tissues, fibroblasts may provide growth factors or participate in the would healing response. Fibroblast play a critical role in wound healing; the synthesis and deposition of extracellular matrix. Fibroblasts commonly become contractile in wound healing environments. Smooth muscle cells - Isolated from arteries, these cells may participate or encourage angiogenesis and/or beneficial cardiac remodeling following MI. MSCs + 5-aza - Culture of mesenchymal stem cells with 5-aza forces differentiation into cardiomyocytes. These cells beat spontaneously after treatment. Adult cardiac fibroblasts + 5-aza - In theory, in vitro treatment of cardiac fibroblasts with 5- aza will result in differentiation into myogenic cells. Genetically modified cells - Isolation of cells from the patient and genetically modifying them in vitro to encourage production of proteins or differentiation into a cell type which will be beneficial for treating heart failure. Tissue engineered grafts - Isolation of cells from the patient which are then seeded onto and cultured within resorbable scaffolds (e.g. collagen, PLGA). These cell seeded constructs are then implanted into the patient. MyoD scar fibroblasts - MyoD family of transcription factors prompt skeletal muscle cell differentiation in fibroblasts. Procedure involves isolation of cardiac scar fibroblasts, genetic transfection with MyoD in vitro and delivery of the cells to the heart to encourage myogenesis. Pacing cells - Genetically modified fibroblasts which become electrically conducting and signal generators. Embryonic stem ceU clones - Use of cloning technology to produce cardiomyocytes, progenitors, or stem ceUs which are geneticaUy identical to the patient. Embryonic stem ceUs - These ceUs are the most primitive of ceUs and wiU differentiate into functional cardiomyocytes under certain conditions. Both political and technological hurdles must be overcome before commercialization of this technology.
Fetal or neonatal ceUs - Isolated from the heart of donors, these ceUs may incorporate into host tissue without immune rejection. Some cardiomyocyte progenitor ceUs must be present due to the continued growth of the heart in fetal and neonatal humans.
ImmunologicaUy masked ceUs - AUogeneic ceU sources (e.g. donor cardiomyocytes) are currently unfeasible due to immune rejection. However, masking technologies have been developed which could make this technology feasible.
Tissue engineered grafts - Isolation of ceUs from a donor which are then seeded onto and cultured within resorbable scaffolds (e.g. coUagen, PLGA). These ceU seeded constructs are then implanted into the host or recipient. GeneticaUy modified ceUs - Isolation of ceUs from a donor and geneticaUy modifying them in vitro to encourage production of proteins or differentiation into a ceU type which wiU be beneficial for treating heart faUure. The modified ceUs will then be transplanted into the host or patient.
Teratoma derived ceUs - A teratocarcinoma is a form of cancer in which the tumor is composed of a heterogeneous mixture of tissues. Through isolation of ceUs from this tumor and in vitro manipulation and culture a neuronal ceU line has been developed. Layton Biosciences has successfuUy used these ceUs to form new brain tissue in stroke patients. SimUar techniques may be used to produce a myogenic ceU line. Where a therapeutic agent comprises at least one polymer agent or coating, the at least one coating may include but is not limited to: polycarboxyUc acids; ceUulosic polymers, including ceUulose acetate and ceUulose nitrate; gelatin; polyvinylpyrroUdone; cross-linked polyvinylpyrroUdone; polyanhydrides including maleic anhydride polymers; polyamides; polyvinyl alcohols; copolymers of vinyl monomers such as EVA; polyvinyl ethers; polyvinyl aromatics; polyethylene oxides; glycosaminoglycans; polysaccharides; polyesters including polyethylene terephthalate; polyacrylamides; polyethers; polyether sulfone; polycarbonate; polyaUcylenes including polypropylene, polyethylene and high molecular weight polyethylene; halogenated polyaUcylenes including polytetrafluoroethylene; polyurethanes; polyorthoesters; proteins; polypeptides; silicones; sUoxane polymers; polylactic acid; polyglycoUc acid; polycaprolactone; polyhydroxybutyrate valerate and blends and copolymers thereof; coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®, etc.), fibrin, coUagen and derivatives thereof; polysaccharides such as ceUuloses, starches, dextrans, alginates and derivatives; hyaluronic acid; squalene emulsions; polyacrylic acid, a copolymer of polylactic acid and polycaprolactone; medical-grade biodegradable materials such as PGA-TMC, Tyrosine-Derived Polycarbonates and arylates; polycaprolactone co butyl acrylate and other co polymers; Poly-L-lactic acid blends with DL-Lactic Acid; Poly(lactic acid-co-glycoUc acid); polycaprolactone co PLA; polycaprolactone co butyl acrylate and other copolymers; Tyrosine-Derived Polycarbonates and arylate; poly arnino acid; polyphosphazenes; polyimino carbonates; polydimethyltrimethylcarbonates; biodegradable CA/PO4 's; cyanoacrylate; 50/50 DLPLG; polydioxanone; polypropylene fumarate; polydepsipeptides; macromolecules such as chitosan and HydroxylpropylmethylceUulose; surface erodible material; maleic anhydride copolymers; zinc-calcium phosphate; amorphous polyanhydrides; sugar; carbohydrate; gelatin; biodegradable polymers; and polymers dissolvable in bodUy fluids; and any combinations thereof. In at least one embodiment an example of a suitable polymer agent or coating comprises block copolymers comprising at least one A block and at least one B block. The A blocks are preferably soft elastomeric blocks, which are based upon one or more polyolefins, or other polymer with a glass transition temperature at or below room temperature. For example, the A blocks can be polyolefihic blocks having alternating quaternary and secondary carbons of the general formulation: -(CRR'-CH2)n-, where R and R are, independently, linear or branched aUphatic groups such as methyl, ethyl, propyl, isopropyL butyl, isobutyl and so forth, or represent cycUc aUphatic groups such as cyclohexane, cyclopentane, and the Uke, either with or without pendant groups. Preferred .CH3 H2C=<^ polyolefinic blocks include polymeric blocks of isobutylene, GH3, (i.e., polymers where R and R' are methyl groups). Other examples of A blocks include siUcone rubber blocks and acrylate rubber blocks. The B blocks are preferably hard thermoplastic blocks with glass transition temperatures significantly higher than the elastomeric A blocks which, when combined with the soft A blocks, are capable of, inter alia, altering or adjusting the hardness of the resulting copolymer to achieve a desired combination of quaUties. Examples of B blocks include polymers of methacrylates or polymers of vinyl aromatics. More specific examples
of B blocks include blocks that are (a) formed from monomers of styrene x>=/ , styrene derivatives (e.g., α-methylstyrene, ring-aUcylated styrenes or ring-halogenated styrenes or other substituted styrenes where one or more substituents are present on the aromatic ring) or mixtures of the same, coUectively referred to herein as "styrenic blocks" or "polystyrenic blocks" or are (b) formed from monomers of methylmethacrylate, ethylmethacrylate, hydroxyethyl methacrylate or mixtures of the same. The block copolymers are provided in a variety of architectures, including cycUc, linear, and branched architectures. Branched architectures include star-shaped architectures (e.g., architectures in which three or more chains emanate from a single region), comb architectures (e.g., copolymers having a main chain and a pluraUty of side chains), and dendritic architectures (including arborescent or hyperbranched copolymers). Some specific examples of such block copolymers include the foUowing: (a) BA
(linear diblock), (b) BAB or ABA (linear triblock), (c) B(AB)n or A(BA)n (linear alternating block), or (d) X-(AB) „ or X-(BA) „ (includes diblock, triblock and other radial block copolymers), where n is a positive whole number and X is a starting seed, or initiator, molecule. One specific group of polymers have X-(AB) „ structures, which are frequently referred to as diblock copolymers and triblock copolymers where n=l and n=2, respectively (this teπriinology disregards the presence of the starting seed molecule, for example, treating A-X-A as a single A block, with the triblock therefore denoted as BAB). A particularly beneficial polymer from this group is polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS). Where n=3 or more, these structures are commonly referred to as star- shaped block copolymers. Other examples of block polymers include branched block copolymers such as dendritic block copolymers, wherein at least one of the A and B blocks is branched, for instance, where the A blocks are branched and are capped by the B blocks. Once the stent 120 is positioned on the assembly 100, such as in the manner shown in FIG. 2, the assembly 100 maybe sUd onto a catheter 116, such as is shown in FIGs 3-4 so that the sheath 102 is rotatingly disposed about the baUoon 114 and a proximal portion 140 of the secondary guidewire housing 104 is engaged to a rotating coUar 150. The collar 150 is engaged to the proximal portion 140 of the secondary guidewire housing 104 by any engagement mechanism desired, such as welding, bonding, mechanical engagement, adhesive engagement, etc. In the embodiments shown in FIG. 14 for example, the proximal portion 140 of the secondary guidewire housing 104 and the coUar 150 are engaged externaUy at engagement site 142. In some embodiments the secondary guidewire housing 104 may be passed at least partiaUy through the coUar 150, and/or the coUar 150 may define a lumen through which the secondary guidewire 108 may be passed before entering into the secondary guidewire housing 104. CoUar 150 maybe a substantially cylindrical member that is disposed about the shaft 144 of the catheter 116 at a position proximal of the baUoon 114. The coUar 150 maybe characterized as defining a catheter shaft lumen 146 through which the catheter shaft 144 is passed. In order to provide the collar 150 with the ability to freely rotate about the catheter shaft 144, the collar 150 defines a catheter shaft lumen 146 which has a diameter greater than the outer diameter of the shaft 144. In some embodiments one or more lubricious substances may be placed between the coUar 150 and the shaft 144 to further encourage free rotation therebetween. While the rotating coUar 150 is free to rotate about the shaft 144, in some embodiments it will also be capable of being longitudinaUy displaced along the shaft 144 as weU. As such, in some embodiments one or more locks or hubs 152 may be affixed about the shaft 144 on one or both sides of the coUar 150 to prevent or limit the potential longitudinal displacement of the coUar 150 relative to the shaft 144. As is shown in FIG. 5, when the assembly 100, including the stent 120 is placed on the catheter 116, the combined system 300 is ready for use in a stent deUvery procedure. However, in some cases it maybe necessary to provide the system 300 with one or more stent retaining elements to retain or aid in retaining the stent in place about the sheath 102. In Ught of the above, however, such elements must be configured so as to not unduly interfere with the rotatability of the assembly 100 about the catheter 116. In at least one embodiment, an example of which is shown in FIG. 10 the stent deUvery system 300 includes a pair of retaining and/or protective sleeves 170 and 172. The sleeves maybe constructed from any of a variety of materials such as are described in U.S. 6,443,980; U.S. 6,221,097; U.S. 6,554,841; U.S. Pub. App. No. 2002-0038140 Al; and U.S. Pub. App. No. 2002-0038141 Al, the entire content of each of which are incorporated herein by reference, but are typicaUy constructed of one or more polymeric and/or elastomeric materials. Sleeves 170 and 172 may function to retain the ends of the baUoon 114 in a reduced state prior to deUvery and/or to aid in deflation and coUapse of the baUoon 114 foUowing deUvery of the stent by providing a radiaUy inward acting force on the ends of the baUoon 114. As is shown in FIG. 10, the sleeves 170 and 172 may be provided with a sufficient length to aUow a first portion 178 of each sleeve to be disposed over a respective proximal end portion 174 and/or distal end portion 176 of the stent 120. When the baUoon 114 is expanded to deUver the stent 120, such as is shown in FIG. 13, the increased diameter of the baUoon 114 and/or stent 120 cause the first portion 178 of each sleeve 170 and 172 to be retract or be puUed off of the end portions 174 and 176 of the stent 120, thereby freeing the stent for deUvery from the system 300. Though sleeves 170 and 172 aid in retaining the stent and/or baUoon in an unexpanded or pre-deUvery state, the each sleeve is also rotatable about the catheter shaft 144, in a manner similar to that of the sheath 102. In order to provide the sleeves with the capacity to rotate, a second portion of each sleeve, corresponding to the portion of the sleeve engaged to the catheter shaft 144, comprises a rigid reinforcing member 179 that is rotatably engaged about the catheter shaft 144. The rigid reinforcing member 179 may be constructed out of any material or materials having a higher durometer value than that of the material or materials from which the retaining or first portion 178 is constructed. As a result the sleeves 170 and 172 wiU have a hybrid construction of at least two materials having different hardnesses. In some embodiments it may be desirable to provide only the distal end of the system 300 with a sleeve 172. Where the system employs a proximal sleeve 170, the proximal sleeve includes an opening 171, such as is best depicted in FIGs. 11 and 12, to accommodate passage of the secondary guidewire housing 104 therethrough. When the baUoon 114 and stent 120 are expanded in the manner shown in FIG. 13, the proximal sleeve 170 may be drawn proximaUy along the secondary guidewire housing 104 and off of the proximal end portion 174 off the stent 120. To encourage ease of retraction, at least a portion of the inside surface 173 of one or both sleeves may be at least partiaUy coated with a lubricious substance. In some embodiments the baUoon 114 is sufficiently folded or otherwise maintained in the unexpanded configuration, such that providing a sleeve or other protective/retaining means over the ends of the baUoon is unnecessary and/or undesirable.
However, it may still be, desirous to cover, or otherwise protect, one or more end portions 174 and 176 of the stent 120. As such, in at least one embodiment of the invention, an example of which in show in FIG. 14, the rotatable sheath 102 includes one or two end portions 180 and 182, which extend beyond the corresponding end portions 174 and 176 of the stent 120. The end portions 180 and 182 comprise flaps 181 and 183, which are configured to be folded or roUed back over the corresponding end portion 174 and 176 of the stent 120, while in the stent is in the unexpanded or pre-deUvery state. Due the to presence of the secondary guidewire housing 104, in some embodiments the only the distal end portion 176 of the stent is overlapped by a distal flap 182 of the sheath 102. However, in some embodiments a proximal flap 181 may have any of a variety of configurations to provide at least partial coverage of the proximal end portion 174 of the stent 120 in the unexpanded state. For example, in FIG. 14 a proximal flap 181 is provided with a tapered shape which aUows the flap to be folded back with an angled configuration to a provide the proximal end portion 174 of the stent 120 with complete or nearly complete coverage in the region opposite from the secondary guidewire housing 104. As the folded flap 181 approaches the region of the secondary guidewire housing 104 the coverage of the proximal end portion of the stent 120 by the flap 181 is reduced in the tapering manner shown. When the stent 120 is expanded, such as in the manner shown in FIG. 15, the flaps 181 and 183 of the sheath 102 wiU sUde off of the respective end portions 174 and 176 of the stent 120 to free the stent for deUvery. In some embodiments the flaps 181 and 183 maybe configured to exert an inwardly acting radial force upon the ends of the baUoon 114 foUowing deUvery of the stent 120, in order to encourage the baUoon to refold or fully coUapse for withdrawal from the body. In some embodiments, the proximal flap 181 may define a slot or opening 184, such as is shown in FIGs 16 and 17. Slot 184 aUows the flap 180 to be folded back over the proximal end portion 174 of the stent 120 to provide a unifonn length of coverage to the stent, excepting the region of the stent 120 wherein the secondary guidewire housing 104 is positioned. In some embodiments it may be desirable to provide the system 300 with a baUoon 114 and/or stent 120 that tends to initiaUy expand initiaUy at a center region to encourage the flaps 180 and 182 to fuUy retract from the stent; such baUoons 114 and stents 120 are known. In the various embodiments, shown in FIGs. 14-17, at least a portion of the stent side surface of the flaps 181 and 183 and/or the corresponding end portions 174 and 176 of the stent 120 may include a lubricious coating thereon to encourage the sUding retraction of the flaps from the stent during expansion. Rather than configuring the sheath 102 to have end portions 180 and 182 which can be folded back over the corresponding end portions 174 and 176 of the stent 120, in some embodiments, an example of which is shown in FIGs. 18 and 19, the end portions 180 and 182 of the sheath define hub regions 185 and 187 which have a greater outside diameter than the stent mounting region 189 of the sheath positioned therebetween. When a stent 120 is mounted in the relatively recessed area of the stent mounting region of the sheath 102, the outer diameter of a distal hub 187 is equal to or greater than the outer diameter of the distal end portion 176 of the stent 120 in the unexpanded state. While in some embodiments the sheath 102 is provided with only a distal hub 187, in some embodiments a proximal hub 185 is also included. In some embodiments, such as those shown in FIGs. 18 and 19 the proximal hub 185 underUes or is adjacent to the secondary guidewire housing 104. This configuration provides the proximal hub 185 with a shape wherein only a "bottom" portion 191 of the proximal hub 185 has an outer diameter greater than that of the stent 120 and a "top" portion 193 of the hub 185 being adjacent to the secondary guidewire housing 104. In some embodiments the secondary guidewire housing 104 maybe bonded, adhered, fused or otherwise engaged to the proximal hub 185. In some embodiments, an example of which is shown in FIG. 19 the secondary guidewire housing 104 may be utilized to protect the area of the proximal end portion 174 of the stent not protected by the top portion of the hub 185. In such embodiments the secondary guidewire housing 104 may include a bent portion 197 which bends around the proximal hub 185 of the sheath 102 prior to passage through the stent 120. This bent portion 197 effectively adds its diameter to that of the proximal hub 185, such that the bent portion 197 extends radiaUy outward to a greater extent than the proximal end portion 174 of the stent 120. As a result, the proximal end portion 174 of the stent 120 is uniformly protected by the combination of the hub 185 and bent portion 197 of the secondary guidewire housing 104. In some embodiments, an example of which is shown in FIG. 20, the proximal hub 185 defines an opening 221, through which the secondary guidewire housing 104 passes. In this embodiment the proximal hub 185 may be shaped and sized to have a diameter that is uniformly larger, or at least equal to, the diameter to the proximal end portion 174 of the stent 120 in the unexpanded state. In the various embodiments of the inventions described above, or alternatively therefrom, the secondary guidewire housing 104 maybe configured to provide the proximal end 174 of the stent 120 with improved edge protection and/or coverage. For example, in the embodiment shown in FIG. 21 , rather than extending the hypotube 64 through the secondary opening 130a of the stent 120, the hypotube 64 terminates adjacent to the proximal end portion 174 of the stent 120. The hypotube 64 may be configured such that a portion of the hypotube 64 is positioned so that it extends radiaUy outward from the system to an extent equal to or greater than the adjacent region of the proximal end portion 174 of the stent 120. In some embodiments the entire secondary guidewire housing 104 is positioned proximaUy adjacent to the stent 120 such that the secondary guidewire 108 exits the housing 104 and passes freely through the secondary opening 130a of the stent 120. To retain the hypotube 64 in a position such that it protects the proximal end portion 174 of the stent 120 in the manner shown in FIG. 21, and described above, the hypotube 64 encloses the inner shaft 103 in an asymmetrical relationship, such as is depicted in the cross- sectional view of FIG. 22. In some embodiments, an example of which is shown in FIG. 23, the hypotube 64 maybe tapered or provided with a stepped configuration where it enters under the proximal end portion 174 of the stent 120. In the embodiment show a portion, of the hypotube 64 proximal to the stent 120 is displaced relative to the stent 120, such that a proximal portion 223 of the hypotube 64 extends radiaUy outward from the system to an extent equal to or greater than the adjacent region of the proximal end portion 174 of the stent 120. A distal portion 225 of the hypotube 64 which extends from the proximal portion 223 tapers or steps down to a reduced diameter portion which extends through the secondary opening 130a of the stent 120. In some embodiments of the invention, one or both cones 190 and 192 of the baUoon 114 may have a "puffed" configuration, such that in the unexpanded state, at least a portion of one or both cones 190 and 192 have a diameter greater than the outside diameter of the sheath 102 and/or stent 120 mounted on the baUoon 114, such as is shown in FIG. 24. In the expanded state, shown in FIG. 26, the cones have a diameter less than that of the stent 120. In the embodiment shown in FIG. 25 only the distal cone 192 is provided with a puffed configuration. The puffed configuration of the cones 190 and 192, shown in FIG. 24 further protects the assembly 100 from longitudinal displacement relative to the catheter 116 during advancement, and provides the stent 120 with similar protection relative to the sheath 102. In keeping with the principles described herein, one or both puffed cones are configured such that they do not interfere with the rotatabiUty of the sheath 102 about the baUoon 114 when in the unexpanded state. It wiU be recognized that the cones 190 and 192 of a baUoon 116 may be provided with the puffed configuration shown in a variety of ways. For example, foUowing assembly of the system 300 fluid may be evacuated from the baUoon 114 while one or both cones 190 and 192 are exposed to vacuum, thereby aUowing the baUoon 114 to attain its folded pre- deUvery configuration whUe simultaneously causing the cones to be distorted or shaped into the puffed configuration shown in FIG. 24. Alternatively, the portion of the baUoon 114 that underUes the sheath 102 may be externaUy retained in the unexpanded state, whUe fluid is injected into the baUoon 116 causing the cones to expand. The cones may be expanded to a degree sufficient to distort the cones 190 and 192 into the puffed configuration shown. It is recognized that other methods of providing one or both cones 190 and 192 with the puffed configuration shown in FIG. 24 and 25 and such methods are within the scope of the invention. The invention has been described with reference to the embodiments.
Obviously, modifications and alterations wiU occur to others upon a reading and understanding of this specification. For example, the illustrated embodiments use a baUoon to expand the stent although, as briefly noted above, a self expanding, self deploying or hybrid expandable stent can be used without departing from the features of the present invention. The invention is intended to include aU such modifications and alterations thereof. Furthermore, it is noted that the various embodiments shown and described in U.S. Patent AppUcation No. 10/375,689, filed February 27, 2003 and U.S. Patent AppUcation o. 10/657,472, filed September 8, 2003, both of which are entitled Rotating Balloon Expandable Sheath Bifurcation Delivery, may be incorporated and/or utilized with the various embodiments described herein. The above disclosure is intended to be illustrative and not exhaustive. This description wiU suggest many variations and alternatives to one of ordinary skill in this art. AU these alternatives and variations are intended to be included within the scope of the claims where the term "comprising" means "including, but not limited to". Those famiUar with the art may recognize other equivalents to the specific embodiments described herein which equivalents are also intended to be encompassed by the claims. Further, the particular features presented in the dependent claims can be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specificaUy directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim pubUcation, any dependent claim which foUows should be taken as alternatively written in a multiple dependent form from aU prior claims which possess aU antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from aU previous claims). In jurisdictions where multiple dependent claim formats are restricted, the foUowing dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim Usted in such dependent claim below. With this description, those skilled in the art may recognize other equivalents to the specific embodiment described herein. Such equivalents are intended to be encompassed by the claims attached hereto.

Claims

CLAIMS:
1. A catheter assembly comprising: a catheter, the catheter comprising a catheter shaft; a rotatable sheath, the rotatable sheath being disposed about at least a portion of the catheter shaft and rotatable thereabout, the rotatable sheath having a length
♦substantiaUy less than that of the catheter shaft, the rotatable sheath comprising a first end region, a second end region and a stent receiving region therebetween; a guidewire housing, the guidewire housing defining a guidewire lumen for passage of a guidewire therethrough, at least a portion of the guidewire housing being engaged to at least a proximal portion of the rotatable sheath; and a stent, the stent being expandable from a reduced stent state to an expanded stent state, in the reduced stent state the stent being disposed about the stent receiving region of the rotatable sheath, the first end of the rotatable sheath extending beyond a proximal end region of the stent and the second end region of the rotatable sheath extending beyond a distal end region of the stent. '
2. The catheter assembly of claim 1 wherein at least a portion of the first end region of the rotatable sheath comprises a proximal flap, in the reduced stent state the proximal flap being positioned over a portion of the proximal end region of the stent, in the expanded stent state the proximal flap being withdrawn from about proximal end region of the stent.
3. The catheter assembly of claim 2 wherein the proximal flap has a first length in a region most proximate to the guidewire housing and a second length in a region furthest from the guidewire housing, the first length being less than the second length, the length of the proximal flap tapering therebetween.
4. The catheter assembly of claim 2 wherein the proximal flap defines a slot, the proximal flap having a circumferential length extending from a first side of the slot to the other side of the slot, the proximal flap having a longitudinal length, the longitudinal length being substantiaUy the same throughout the circumferential length.
5. The catheter assembly of claim 1 wherein at least a portion of the second end region of the rotatable sheath comprises a distal flap, in the reduced stent state the distal flap being positioned over a portion of the distal end region of the stent, in the expanded stent state the distal flap being withdrawn from about distal end region of the stent.
6. The catheter assembly of claim 1 wherein at least a portion of the first end region of the rotatable sheath comprises a proximal flap, and at least a portion of the second end region of the rotatable sheath comprises a distal flap, in the reduced stent state the proximal flap being positioned over a portion of the proximal end region of the stent, in the expanded stent state the proximal flap being withdrawn from about proximal end region of the stent, in the reduced stent state the distal flap being positioned over a portion of the distal end region of the stent, in the expanded stent state the distal flap being withdrawn from about distal end region of the stent.
7. The catheter assembly of claim 6 wherein at least one of the proximal flap and the distal flap comprise a lubricious coating.
8. The catheter assembly of claim 1 wherein the rotatable sheath has an outer diameter, the outer diameter of the stent receiving region being less than the outer diameter of the first end region and the outer diameter of the a second end region.
9. The catheter assembly of claim 8 wherein the stent has an outer diameter, in the reduced stent state the outer diameter of the distal end region of the stent being no greater than the outer diameter of the second end region of the rotatable sheath.
10. The catheter assembly of claim 8 wherein the stent has an outer diameter, in the reduced stent state the outer diameter of the proximal end region of the stent being no greater than the outer diameter of the first end region of the rotatable sheath.
11. The catheter assembly of claim 10 wherein the first end region of the rotatable sheath is engaged to at least a portion of the guidewire housing.
12. The catheter assembly of claim 11 wherein the first end region of the rotatable sheath defines an opening, the guidewire housing extending through the opening.
13. The catheter assembly of claim 10 wherein the at least a portion of the guidewire housing is proximaUy adjacent to the proximal end region of the stent, the at least a portion of the guidewire housing being radiaUy offset from the outer diameter of the proximal end region of the stent.
14. The catheter assembly of claim 1 wherein the guidewire housing is comprised of an outer guidewire housing and an inner guidewire housing, ϊn the reduced stent state the outer guidewire housing being proximaUy adjacent to the proximal end region of the stent, at least a portion of the outer guidewire housing being radiaUy offset from the proximal end region of the stent, the inner guidewire housing extending from the outer guide wire housing through at least a portion of the stent.
15. The catheter assembly of claim 1 wherein the guidewire housing comprises a proximal portion and a distal portion, the proximal portion having a diameter greater than that of the distal portion, in the reduced stent state the proximal portion of the guidewire housing being proximaUy adjacent to and radiaUy offset from the proximal end region of the stent, the distal portion of the guidewire housing extending through at least a portion of the stent.
16. The catheter assembly of claim 1 wherein the catheter shaft comprises a baUoon, the baUoon being expandable from and between a reduced diameter configuration and an expanded diameter configuration, the rotatable sheath being rotatably disposed about at least a portion of the balloon, the rotatable sheath being expand from a reduced sheath diameter when the baUoon is in the reduced diameter configuration to an expanded sheath diameter when the baUoon is in the expanded diameter configuration.
17. The catheter assembly of claim 16 wherein the baUoon comprises a proximal baUoon cone, a distal baUoon cone and a rotatable sheath receiving region therebetween, the rotatable sheath being positioned on the rotatable sheath receiving region, such that the first portion of the rotatable sheath is distaUy adjacent the proximal baUoon cone and the second portion of the rotatable sheath is proximaUy adjacent the distal baUoon cone.
18. The catheter assembly of claim 17 wherein when the baUoon is in the reduced diameter configuration, at least a portion of at least one of the proximal baUoon cone and the distal baUoon cone has an outer diameter greater than that of the rotatable sheath.
19. The catheter assembly of claim 17, wherein when the baUoon is in the reduced diameter configuration, at least a portion of the distal baUoon cone has an outer diameter greater than that of the distal end region of the stent.
20. The catheter assembly of claim 17, wherein when the baUoon is in the reduced diameter configuration, at least a portion of the proximal baUoon cone is radiaUy offset from a portion of the proximal end region of the stent.
21. The catheter assembly of claim 1 further comprising a distal sleeve, the distal sleeve comprising a first sleeve region and a second sleeve region, in the reduced stent state at least a portion of the first sleeve region being disposed about the second end region of the rotatable sheath and the distal end region of the stent, the second sleeve region being rotatably engaged to a portion of the catheter shaft distaUy adjacent to the second end region of the rotatable sheath.
22. The catheter assembly of claim 21 wherein the first sleeve region is constructed of at least one first material and the second sleeve region is constructed of at least one second material, the at least on second material having a higher durometer value than the at least one first material.
23. The catheter assembly of claim 22 wherein in the expanded stent configuration the distal sleeve is retracted from about the second end region of the rotatable sheath and the i distal end region of the stent.
24. The catheter assembly of claim 21 further comprising a proximal sleeve, the proximal sleeve comprising a first sleeve region and a second sleeve region, in the reduced stent state at least a portion of the first sleeve region of the proximal sleeve being disposed about the first end region of the rotatable sheath and the proximal end region of the stent, the second sleeve region of the proximal sleeve being rotatably engaged to a portion of the catheter shaft proximaUy adjacent to the first end region of the rotatable sheath.
25. The catheter assembly of claim 24 wherein the proximal sleeve defines an opening the guidewire housing passing through the opening.
26. The catheter assembly of claim 25 wherein in the expanded stent configuration the proximal sleeve is retracted from about the first end region of the rotatable sheath and the proximal end region of the stent, the proximal sleeve being drawn proximaUy along the guidewire housing.
27. The catheter assembly of claim 1 wherein the stent is selected from at least one member of the group consisting of: a self-expanding stent, a baUoon-expandable stent, a hybrid expandable stent and any combination thereof.
28. The catheter assembly of claim 27 wherein at least a portion of the stent is coated with at least one therapeutic agent.
29. The catheter assembly of claim 28 wherein the at least one therapeutic agent is at least one non-genetic therapeutic agent selected from at least one member of the group consisting of: anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-proUferative agents such as enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle ceU proUferation, hirudiii, and acetylsaUcyUc acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproUferative/anti-miotic agents such as pacUtaxel, 5- fluorouracU, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; vascular ceU growth promoters such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters, vascular ceU growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin; biftmctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodUating agents; and agents which interfere with endogenous vascoactive mechanisms, and any combinations thereof.
30. The catheter assembly of claim 28 wherein the at least one therapeutic agent is at least one genetic therapeutic agent selected from at least one member of the group consisting of: anti-sense DNA and RNA; DNA coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules; angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endotheUal growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endotheUal growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin Uke growth factor; ceU cycle inhibitors including CD inhibitors, thymidine kinase ("TK") and other agents useful for interfering with ceU proUferation; at least one of the family of bone morphogenic proteins ("BMP's") such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP- 14, BMP- 15, and BMP-16. Any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7; dimeric proteins such as homodimers, heterodimers, or combinations thereof, alone or together with other molecules; molecules capable of inducing an upstream or downstream effect of a BMP such as "hedgehog" proteins, or the DNA's encoding them and any combinations thereof.
31. The catheter assembly of claim 28 wherein the at least one therapeutic agent is at least one type of ceUular material selected from at least one member of the group consisting of: ceUs of human origin (autologous or aUogeneic); ceUs of non-human origin (xenogeneic) and any combination thereof.
32. The catheter assembly of claim 31 wherein the ceUular material is selected from at least one member of the group consisting of: side population ceUs; lineage negative ceUs; lineage negative CD34" ceUs; lineage negative CD34+ ceUs; lineage negative "cKit+ ceUs; mesenchymal stem ceUs; cord blood beUs; cardiac or other tissue derived stem ceUs; whole bone marrow; bone marrow mononuclear ceUs; endotheUal progenitor ceUs; satellite ceUs; muscle derived ceUs; go ceUs; endotheUal ceUs; adult cardiomyocytes; fibroblasts; smooth muscle ceUs; cultures of mesenchymal stem ceUs with 5-aza forces differentiation into cardiomyocytes; adult cardiac fibroblasts + 5-aza; geneticaUy modified ceUs; tissue engineered grafts; MyoD scar fibroblasts; Pacing ceUs; embryonic stem ceU clones; embryonic stem ceUs; fetal or neonatal ceUs; immunologicaUy masked ceUs; tissue engineered grafts; geneticaUy modified ceUs; teratoma derived ceUs and any combinations thereof.
33. The catheter assembly of claim 28 wherein the at least one therapeutic agent comprises at least one polymer coating, the at least one coating selected from at least one member of the group consisting of: polycarboxyUc acids; ceUulosic polymers, including ceUulose acetate and ceUulose nitrate; gelatin; polyvinylpyrroUdone; cross-linked polyvinylpyrroUdone; polyanhydrides including maleic anhydride polymers; polyamides; polyvinyl alcohols; copolymers of vinyl monomers such as EVA; polyvinyl ethers; polyvinyl aromatics; polyethylene oxides; glycosaminoglycans; polysaccharides; polyesters including polyethylene terephthalate; polyacrylamides; polyethers; polyether sulfone; polycarbonate; polyaUcylenes including polypropylene, polyethylene and high molecular weight polyethylene; halogenated polyaUcylenes including polytetrafluoroethylene; polyurethanes; polyorthoesters; proteins; polypeptides; silicones; sUoxane polymers; polylactic acid; polyglycoUc acid; polycaprolactone; polyhydroxybutyrate valerate and blends and copolymers thereof; coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®, etc.), fibrin, coUagen and derivatives thereof; polysaccharides such as ceUuloses, starches, dextrans, alginates and derivatives; hyaluronic acid; squalene emulsions; polyacryUc acid, a copolymer of polylactic acid and polycaprolactone; medical-grade biodegradable materials such as PGA-TMC, Tyrosine-Derived Polycarbonates and arylates; polycaprolactone co butyl acrylate and other co polymers; Poly-L-lactic acid blends with DL-Lactic Acid; Poly(lactic acid-co-glycoUc acid); polycaprolactone co PLA; polycaprolactone co butyl acrylate and other copolymers; Tyrosine-Derived Polycarbonates and arylate; poly arnino acid; polyphosphazenes; polyiminocarbonates; polydimethyltrimethylcarbonates; biodegradable CA/PO 's; cyanoacrylate; 50/50 DLPLG; polydioxanone; polypropylene fiin arate; polydepsipeptides; macromolecules such as chitosan and HydroxylpropylmethylceUulose; surface erodible material; maleic anhydride copolymers; zinc-calcium phosphate; amorphous polyanhydrides; sugar; carbohydrate; gelatin; biodegradable polymers; and polymers dissolvable in bodUy fluids; A block copolymers; B block copolymers and any combinations thereof.
34. The catheter assembly of claim 1 further comprising a lubricious coating, the lubricious coating positioned between at least a portion of the rotatable sheath and the at least a portion of the catheter shaft.
35. The catheter assembly of claim 1 further comprising a rotatable coUar, the rotatable coUar rotatably disposed about a portion of the catheter shaft proximal of the rotatable sheath, at least a portion of the guidewire housing being engaged to at least a portion of the rotatable coUar.
36. The catheter assembly of claim 1 wherein the rotatable sheath is at least partiaUy constructed from a hydrophiUc polymer material.
37. The catheter assembly of claim 1 wherein the rotatable sheath is at least partiaUy constructed from a tecophUic material.
38. The catheter assembly of claim 1 wherein the rotatable sheath is at least partiaUy constructed from a first material and a second material.
39. The catheter assembly of claim 38 wherein the rotatable sheath is at least partiaUy constructed from at least one material of the group consisting of: hydrophiUc polyurethanes, aromatic polyurethanes, polycarbonate base aUphatic polyurethanes, engineering polyurethane, elastomeric polyamides, block polyamide/ethers, polyether block amide, siUcones, polyether-ester, polyester, polyester elastomer, polyethylene, polyamide, high- density polyethylene, polyetheretherketone, polyimide, polyetherimide, Uquid crystal polymers, acetal, and any combination thereof.
40. The catheter assembly of claim 38 wherein the first material is a polymer matrix and the second material is at least one distinct member of reinforcing material at least partiaUy supported witfiin the polymer matrix.
41. The catheter assembly of claim 40 wherein polymer matrix is selected from at least one material from the group consisting of: hydrophiUc polyurethanes, aromatic polyurethanes, polycarbonate base aUphatic polyurethanes, engineering polyurethane, elastomeric polyamides, block polyamide/ethers, polyether block amide, sUicones, polyether-ester, polyester, polyester elastomer, polyethylene and any combination thereof.
42. The assembly of claim 40 wherein the reinforcing material is selected from at least one material of the group consisting of polyamide, polyethylene, high-density polyethylene, polyetheretherketone, polyimide, polyetherimide, Uquid crystal polymers, acetal, and any combination thereof.
PCT/US2004/034360 2003-12-29 2004-10-18 Rotating balloon expandable sheath bifurcation delivery system WO2005067818A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006546974A JP4740153B2 (en) 2003-12-29 2004-10-18 Catheter assembly
CA002550529A CA2550529A1 (en) 2003-12-29 2004-10-18 Rotating balloon expandable sheath bifurcation delivery system
EP04795507A EP1708644A1 (en) 2003-12-29 2004-10-18 Rotating balloon expandable sheath bifurcation delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/747,546 US7686841B2 (en) 2003-12-29 2003-12-29 Rotating balloon expandable sheath bifurcation delivery system
US10/747,546 2003-12-29

Publications (1)

Publication Number Publication Date
WO2005067818A1 true WO2005067818A1 (en) 2005-07-28

Family

ID=34710809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/034360 WO2005067818A1 (en) 2003-12-29 2004-10-18 Rotating balloon expandable sheath bifurcation delivery system

Country Status (5)

Country Link
US (1) US7686841B2 (en)
EP (1) EP1708644A1 (en)
JP (1) JP4740153B2 (en)
CA (1) CA2550529A1 (en)
WO (1) WO2005067818A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036263A1 (en) * 2004-09-28 2006-04-06 Boston Scientific Limited Rotatable sheath, assembly and method of manufacture of same
US7686841B2 (en) 2003-12-29 2010-03-30 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery system
WO2010133668A2 (en) 2009-05-20 2010-11-25 Fh Campus Wien Eukaryotic host cell comprising an expression enhancer
US7922753B2 (en) 2004-01-13 2011-04-12 Boston Scientific Scimed, Inc. Bifurcated stent delivery system
US8012192B2 (en) 2004-02-18 2011-09-06 Boston Scientific Scimed, Inc. Multi-stent delivery system
US10863997B2 (en) 2016-03-25 2020-12-15 Asahi Intecc Co., Ltd. Medical device

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723931B1 (en) * 1996-11-04 2012-01-04 Advanced Stent Technologies, Inc. Extendible stent apparatus and method for deploying the same
US6599316B2 (en) 1996-11-04 2003-07-29 Advanced Stent Technologies, Inc. Extendible stent apparatus
US6325826B1 (en) 1998-01-14 2001-12-04 Advanced Stent Technologies, Inc. Extendible stent apparatus
US7341598B2 (en) 1999-01-13 2008-03-11 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US6835203B1 (en) 1996-11-04 2004-12-28 Advanced Stent Technologies, Inc. Extendible stent apparatus
US8257425B2 (en) 1999-01-13 2012-09-04 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
AU2002250189A1 (en) 2001-02-26 2002-09-12 Scimed Life Systems, Inc. Bifurcated stent and delivery system
DE60229852D1 (en) 2001-08-23 2008-12-24 Darrell C Gumm ROTATING STENT FEEDING SYSTEM FOR INTRODUCING TO A SIDE BRANCH AND PROTECTION
KR100893070B1 (en) * 2002-09-19 2009-04-17 엘지전자 주식회사 Method and apparatus for providing and receiving multicast service in a radio communication system
US7314480B2 (en) * 2003-02-27 2008-01-01 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery
US8298280B2 (en) 2003-08-21 2012-10-30 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US7744619B2 (en) 2004-02-24 2010-06-29 Boston Scientific Scimed, Inc. Rotatable catheter assembly
US7922740B2 (en) 2004-02-24 2011-04-12 Boston Scientific Scimed, Inc. Rotatable catheter assembly
US9050437B2 (en) * 2004-03-04 2015-06-09 YMED, Inc. Positioning device for ostial lesions
US7766951B2 (en) * 2004-03-04 2010-08-03 Y Med, Inc. Vessel treatment devices
US8007528B2 (en) 2004-03-17 2011-08-30 Boston Scientific Scimed, Inc. Bifurcated stent
US20050273149A1 (en) * 2004-06-08 2005-12-08 Tran Thomas T Bifurcated stent delivery system
EP1753369B1 (en) 2004-06-08 2013-05-29 Advanced Stent Technologies, Inc. Stent with protruding branch portion for bifurcated vessels
US7635383B2 (en) * 2004-09-28 2009-12-22 Boston Scientific Scimed, Inc. Rotating stent delivery system for side branch access and protection and method of using same
US7699883B2 (en) * 2004-10-25 2010-04-20 Myles Douglas Vascular graft and deployment system
US9427340B2 (en) 2004-12-14 2016-08-30 Boston Scientific Scimed, Inc. Stent with protruding branch portion for bifurcated vessels
US8317855B2 (en) 2005-05-26 2012-11-27 Boston Scientific Scimed, Inc. Crimpable and expandable side branch cell
US8480728B2 (en) 2005-05-26 2013-07-09 Boston Scientific Scimed, Inc. Stent side branch deployment initiation geometry
US7927362B2 (en) * 2005-07-21 2011-04-19 Boston Scientific Scimed, Inc. Laser ablated elastomer sheath profiles to enables stent securement
US8038706B2 (en) 2005-09-08 2011-10-18 Boston Scientific Scimed, Inc. Crown stent assembly
US8043366B2 (en) 2005-09-08 2011-10-25 Boston Scientific Scimed, Inc. Overlapping stent
US7731741B2 (en) 2005-09-08 2010-06-08 Boston Scientific Scimed, Inc. Inflatable bifurcation stent
US20070112418A1 (en) 2005-11-14 2007-05-17 Boston Scientific Scimed, Inc. Stent with spiral side-branch support designs
US7766893B2 (en) * 2005-12-07 2010-08-03 Boston Scientific Scimed, Inc. Tapered multi-chamber balloon
US8435284B2 (en) 2005-12-14 2013-05-07 Boston Scientific Scimed, Inc. Telescoping bifurcated stent
US8343211B2 (en) 2005-12-14 2013-01-01 Boston Scientific Scimed, Inc. Connectors for bifurcated stent
US7540881B2 (en) 2005-12-22 2009-06-02 Boston Scientific Scimed, Inc. Bifurcation stent pattern
US20070168013A1 (en) * 2006-01-19 2007-07-19 Myles Douglas Vascular graft and deployment system
US8926679B2 (en) 2006-03-03 2015-01-06 Boston Scientific Scimed, Inc. Bifurcated stent system balloon folds
US20070208408A1 (en) * 2006-03-06 2007-09-06 Boston Scientific Scimed, Inc. Non-foreshortening sheaths and assemblies for use
US7833264B2 (en) 2006-03-06 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent
US20070208415A1 (en) * 2006-03-06 2007-09-06 Kevin Grotheim Bifurcated stent with controlled drug delivery
US8298278B2 (en) 2006-03-07 2012-10-30 Boston Scientific Scimed, Inc. Bifurcated stent with improvement securement
US9757260B2 (en) 2006-03-30 2017-09-12 Medtronic Vascular, Inc. Prosthesis with guide lumen
US7951186B2 (en) * 2006-04-25 2011-05-31 Boston Scientific Scimed, Inc. Embedded electroactive polymer structures for use in medical devices
US20070249909A1 (en) * 2006-04-25 2007-10-25 Volk Angela K Catheter configurations
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US20070260304A1 (en) * 2006-05-02 2007-11-08 Daniel Gregorich Bifurcated stent with minimally circumferentially projected side branch
US7922758B2 (en) 2006-06-23 2011-04-12 Boston Scientific Scimed, Inc. Nesting twisting hinge points in a bifurcated petal geometry
US8439961B2 (en) * 2006-07-31 2013-05-14 Boston Scientific Scimed, Inc. Stent retaining mechanisms
US9044350B2 (en) * 2006-08-21 2015-06-02 Boston Scientific Scimed, Inc. Alignment sheath apparatus and method
EP2468314A1 (en) * 2006-09-06 2012-06-27 Boston Scientific Limited Medical devices having a coating for promoting endothelial cell adhesion
US8216267B2 (en) 2006-09-12 2012-07-10 Boston Scientific Scimed, Inc. Multilayer balloon for bifurcated stent delivery and methods of making and using the same
US7951191B2 (en) 2006-10-10 2011-05-31 Boston Scientific Scimed, Inc. Bifurcated stent with entire circumferential petal
US8206429B2 (en) 2006-11-02 2012-06-26 Boston Scientific Scimed, Inc. Adjustable bifurcation catheter incorporating electroactive polymer and methods of making and using the same
US8414611B2 (en) * 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Main vessel constraining side-branch access balloon
US8398695B2 (en) 2006-11-03 2013-03-19 Boston Scientific Scimed, Inc. Side branch stenting system using a main vessel constraining side branch access balloon and side branching stent
WO2008063496A2 (en) * 2006-11-13 2008-05-29 Flexible Stenting Solutions, Llc Delivery system catheter with rotating distal end
US9622888B2 (en) 2006-11-16 2017-04-18 W. L. Gore & Associates, Inc. Stent having flexibly connected adjacent stent elements
US7842082B2 (en) 2006-11-16 2010-11-30 Boston Scientific Scimed, Inc. Bifurcated stent
US8795346B2 (en) * 2006-11-20 2014-08-05 Boston Scientific Scimed, Inc. Semi rigid edge protection design for stent delivery system
US7959668B2 (en) * 2007-01-16 2011-06-14 Boston Scientific Scimed, Inc. Bifurcated stent
WO2008113005A2 (en) * 2007-03-15 2008-09-18 Boston Scientific Scimed, Inc. Methods to improve the stability of cellular adhesive proteins and peptides
US8118861B2 (en) 2007-03-28 2012-02-21 Boston Scientific Scimed, Inc. Bifurcation stent and balloon assemblies
US8647376B2 (en) 2007-03-30 2014-02-11 Boston Scientific Scimed, Inc. Balloon fold design for deployment of bifurcated stent petal architecture
US8025636B2 (en) * 2007-05-02 2011-09-27 Boston Scientific Scimed, Inc. Balloon catheters
US7959669B2 (en) 2007-09-12 2011-06-14 Boston Scientific Scimed, Inc. Bifurcated stent with open ended side branch support
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US20090226501A1 (en) * 2007-12-07 2009-09-10 Boston Scientific Scimed, Inc. Drug coated stent with endosome-disrupting conjugate
US8277501B2 (en) 2007-12-21 2012-10-02 Boston Scientific Scimed, Inc. Bi-stable bifurcated stent petal geometry
WO2009088953A2 (en) 2007-12-31 2009-07-16 Boston Scientific Scimed Inc. Bifurcation stent delivery system and methods
US8926688B2 (en) 2008-01-11 2015-01-06 W. L. Gore & Assoc. Inc. Stent having adjacent elements connected by flexible webs
US8333003B2 (en) 2008-05-19 2012-12-18 Boston Scientific Scimed, Inc. Bifurcation stent crimping systems and methods
US8932340B2 (en) 2008-05-29 2015-01-13 Boston Scientific Scimed, Inc. Bifurcated stent and delivery system
US20100030192A1 (en) * 2008-08-01 2010-02-04 Boston Scientific Scimed, Inc. Catheter shaft bond arrangements and methods
US8715331B2 (en) * 2008-08-06 2014-05-06 Boston Scientific Scimed, Inc. Stent edge protection and methods
US8133199B2 (en) 2008-08-27 2012-03-13 Boston Scientific Scimed, Inc. Electroactive polymer activation system for a medical device
US8574612B2 (en) * 2009-03-04 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having a coating of biologic macromolecules
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
US9675414B2 (en) 2012-09-13 2017-06-13 Boston Scientific Scimed, Inc. Renal nerve modulation balloon and methods of making and using the same
US9693821B2 (en) 2013-03-11 2017-07-04 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014163987A1 (en) 2013-03-11 2014-10-09 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
JP6220044B2 (en) 2013-03-15 2017-10-25 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Medical device for renal nerve ablation
AU2014237950B2 (en) 2013-03-15 2017-04-13 Boston Scientific Scimed, Inc. Control unit for use with electrode pads and a method for estimating an electrical leakage
WO2014205399A1 (en) 2013-06-21 2014-12-24 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
WO2014205388A1 (en) 2013-06-21 2014-12-24 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
EP3016605B1 (en) 2013-07-01 2019-06-05 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
CN105377170A (en) 2013-07-11 2016-03-02 波士顿科学国际有限公司 Medical device with stretchable electrode assemblies
CN105682594B (en) 2013-07-19 2018-06-22 波士顿科学国际有限公司 Helical bipolar electrodes renal denervation dominates air bag
WO2015013205A1 (en) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
WO2015013301A1 (en) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
EP4049605A1 (en) 2013-08-22 2022-08-31 Boston Scientific Scimed Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
CN105555218B (en) 2013-09-04 2019-01-15 波士顿科学国际有限公司 With radio frequency (RF) foley's tube rinsed with cooling capacity
CN105530885B (en) 2013-09-13 2020-09-22 波士顿科学国际有限公司 Ablation balloon with vapor deposited covering
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
CN105636537B (en) 2013-10-15 2018-08-17 波士顿科学国际有限公司 Medical instrument sacculus
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
EP3057521B1 (en) 2013-10-18 2020-03-25 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
CN105899157B (en) 2014-01-06 2019-08-09 波士顿科学国际有限公司 Tear-proof flexible circuit assembly
CN106572881B (en) 2014-02-04 2019-07-26 波士顿科学国际有限公司 Substitution of the heat sensor on bipolar electrode is placed
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US10299948B2 (en) 2014-11-26 2019-05-28 W. L. Gore & Associates, Inc. Balloon expandable endoprosthesis
US10568752B2 (en) 2016-05-25 2020-02-25 W. L. Gore & Associates, Inc. Controlled endoprosthesis balloon expansion

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749825A (en) 1996-09-18 1998-05-12 Isostent, Inc. Means method for treatment of stenosed arterial bifurcations
US6221097B1 (en) 1999-03-22 2001-04-24 Scimed Life System, Inc. Lubricated sleeve material for stent delivery
US20020038141A1 (en) 2000-09-22 2002-03-28 Dachuan Yang Sandwich striped sleeve for stent delively
US20020038140A1 (en) 2000-09-22 2002-03-28 Dachuan Yang Hybrid elastomer sleeve for stent delivery
US20020072755A1 (en) * 2000-12-08 2002-06-13 Bigus Stephen J. Catheter with rotatable balloon
US6443980B1 (en) 1999-03-22 2002-09-03 Scimed Life Systems, Inc. End sleeve coating for stent delivery
WO2003017872A1 (en) * 2001-08-23 2003-03-06 Scimed Life Systems Inc Rotating stent delivery system for side branch access and protection and method of using same.
US20040172121A1 (en) * 2003-02-27 2004-09-02 Tracee Eidenschink Rotating balloon expandable sheath bifurcation delivery
WO2004075792A1 (en) * 2003-02-27 2004-09-10 Boston Scientific Limited Stent delivery system with a balloon catheter surrounded by a rotating sheath

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448195A (en) * 1981-05-08 1984-05-15 Leveen Harry H Reinforced balloon catheter
FR2512665A1 (en) 1981-09-12 1983-03-18 Wolf Gmbh Richard CATHETER FOR MEASURING INTRA-URETRAL PRESSURE
US4601701A (en) * 1985-02-25 1986-07-22 Argon Medical Corp. Multi-purpose multi-lumen catheter
US5449343A (en) 1985-07-30 1995-09-12 Advanced Cardiovascular Systems, Inc. Steerable dilatation catheter
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4769005A (en) 1987-08-06 1988-09-06 Robert Ginsburg Selective catheter guide
US4998923A (en) * 1988-08-11 1991-03-12 Advanced Cardiovascular Systems, Inc. Steerable dilatation catheter
CA1322628C (en) * 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5019085A (en) * 1988-10-25 1991-05-28 Cordis Corporation Apparatus and method for placement of a stent within a subject vessel
US4913141A (en) * 1988-10-25 1990-04-03 Cordis Corporation Apparatus and method for placement of a stent within a subject vessel
US5120308A (en) * 1989-05-03 1992-06-09 Progressive Angioplasty Systems, Inc. Catheter with high tactile guide wire
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5843089A (en) * 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5122154A (en) * 1990-08-15 1992-06-16 Rhodes Valentine J Endovascular bypass graft
AR246020A1 (en) * 1990-10-03 1994-03-30 Hector Daniel Barone Juan Carl A ball device for implanting an intraluminous aortic prosthesis, for repairing aneurysms.
EP0492361B1 (en) * 1990-12-21 1996-07-31 Advanced Cardiovascular Systems, Inc. Fixed-wire dilatation catheter with rotatable balloon assembly
CA2060067A1 (en) * 1991-01-28 1992-07-29 Lilip Lau Stent delivery system
US5329923A (en) 1991-02-15 1994-07-19 Lundquist Ingemar H Torquable catheter
US5219335A (en) 1991-05-23 1993-06-15 Scimed Life Systems, Inc. Intravascular device such as introducer sheath or balloon catheter or the like and methods for use thereof
FR2678508B1 (en) 1991-07-04 1998-01-30 Celsa Lg DEVICE FOR REINFORCING VESSELS OF THE HUMAN BODY.
US5316023A (en) * 1992-01-08 1994-05-31 Expandable Grafts Partnership Method for bilateral intra-aortic bypass
US5246421A (en) 1992-02-12 1993-09-21 Saab Mark A Method of treating obstructed regions of bodily passages
US5257974A (en) 1992-08-19 1993-11-02 Scimed Life Systems, Inc. Performance enhancement adaptor for intravascular balloon catheter
US5562725A (en) 1992-09-14 1996-10-08 Meadox Medicals Inc. Radially self-expanding implantable intraluminal device
US5634901A (en) * 1992-11-02 1997-06-03 Localmed, Inc. Method of using a catheter sleeve
US5336178A (en) 1992-11-02 1994-08-09 Localmed, Inc. Intravascular catheter with infusion array
US5449382A (en) 1992-11-04 1995-09-12 Dayton; Michael P. Minimally invasive bioactivated endoprosthesis for vessel repair
US5843167A (en) 1993-04-22 1998-12-01 C. R. Bard, Inc. Method and apparatus for recapture of hooked endoprosthesis
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5989280A (en) * 1993-10-22 1999-11-23 Scimed Lifesystems, Inc Stent delivery apparatus and method
DE69419877T2 (en) * 1993-11-04 1999-12-16 Bard Inc C R Fixed vascular prosthesis
AU686315B2 (en) 1994-02-07 1998-02-05 Kabushikikaisya Igaki Iryo Sekkei Stent device and stent supply system
US5609627A (en) * 1994-02-09 1997-03-11 Boston Scientific Technology, Inc. Method for delivering a bifurcated endoluminal prosthesis
US6120523A (en) 1994-02-24 2000-09-19 Radiance Medical Systems, Inc. Focalized intraluminal balloons
US5556413A (en) 1994-03-11 1996-09-17 Advanced Cardiovascular Systems, Inc. Coiled stent with locking ends
US6165210A (en) 1994-04-01 2000-12-26 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US6001123A (en) * 1994-04-01 1999-12-14 Gore Enterprise Holdings Inc. Folding self-expandable intravascular stent-graft
US5824044A (en) 1994-05-12 1998-10-20 Endovascular Technologies, Inc. Bifurcated multicapsule intraluminal grafting system
US5824041A (en) 1994-06-08 1998-10-20 Medtronic, Inc. Apparatus and methods for placement and repositioning of intraluminal prostheses
US6331188B1 (en) * 1994-08-31 2001-12-18 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US6015429A (en) * 1994-09-08 2000-01-18 Gore Enterprise Holdings, Inc. Procedures for introducing stents and stent-grafts
US5683345A (en) 1994-10-27 1997-11-04 Novoste Corporation Method and apparatus for treating a desired area in the vascular system of a patient
US5779688A (en) * 1994-10-28 1998-07-14 Intella Interventional Systems, Inc. Low profile balloon-on-a-wire catheter with shapeable and/or deflectable tip and method
CA2175720C (en) * 1996-05-03 2011-11-29 Ian M. Penn Bifurcated stent and method for the manufacture and delivery of same
NL9500094A (en) * 1995-01-19 1996-09-02 Industrial Res Bv Y-shaped stent and method of deployment.
US5643278A (en) * 1995-04-06 1997-07-01 Leocor, Inc. Stent delivery system
US5807398A (en) * 1995-04-28 1998-09-15 Shaknovich; Alexander Shuttle stent delivery catheter
US6322548B1 (en) 1995-05-10 2001-11-27 Eclipse Surgical Technologies Delivery catheter system for heart chamber
DE69634013T2 (en) 1995-05-26 2005-12-15 SurModics, Inc., Eden Prairie PROCESS AND IMPLANTABLE OBJECT FOR PROMOTING ENDOTHELIALIZATION
WO1996040349A1 (en) * 1995-06-07 1996-12-19 Advanced Cardiovascular Systems, Inc. Sheath for an adjustable length balloon
AU5776696A (en) * 1995-06-08 1997-01-09 Bard Galway Limited Bifurcated endovascular stent
US5776141A (en) * 1995-08-28 1998-07-07 Localmed, Inc. Method and apparatus for intraluminal prosthesis delivery
US6027460A (en) * 1995-09-14 2000-02-22 Shturman Cardiology Systems, Inc. Rotatable intravascular apparatus
US5776161A (en) * 1995-10-16 1998-07-07 Instent, Inc. Medical stents, apparatus and method for making same
US6436104B2 (en) 1996-01-26 2002-08-20 Cordis Corporation Bifurcated axially flexible stent
US6533805B1 (en) * 1996-04-01 2003-03-18 General Surgical Innovations, Inc. Prosthesis and method for deployment within a body lumen
US6629981B2 (en) 2000-07-06 2003-10-07 Endocare, Inc. Stent delivery system
UA58485C2 (en) * 1996-05-03 2003-08-15 Медінол Лтд. Method for manufacture of bifurcated stent (variants) and bifurcated stent (variants)
US5670161A (en) 1996-05-28 1997-09-23 Healy; Kevin E. Biodegradable stent
WO1997045073A1 (en) * 1996-05-31 1997-12-04 Bard Galway Limited Bifurcated endovascular stents and method and apparatus for their placement
US7238197B2 (en) 2000-05-30 2007-07-03 Devax, Inc. Endoprosthesis deployment system for treating vascular bifurcations
US5697971A (en) 1996-06-11 1997-12-16 Fischell; Robert E. Multi-cell stent with cells having differing characteristics
US5797952A (en) * 1996-06-21 1998-08-25 Localmed, Inc. System and method for delivering helical stents
US5836952A (en) 1996-08-21 1998-11-17 Cordis Corporation Hand-held stent crimper
US5968068A (en) * 1996-09-12 1999-10-19 Baxter International Inc. Endovascular delivery system
US5772669A (en) 1996-09-27 1998-06-30 Scimed Life Systems, Inc. Stent deployment catheter with retractable sheath
US5725519A (en) * 1996-09-30 1998-03-10 Medtronic Instent Israel Ltd. Stent loading device for a balloon catheter
US5755778A (en) * 1996-10-16 1998-05-26 Nitinol Medical Technologies, Inc. Anastomosis device
US7591846B2 (en) 1996-11-04 2009-09-22 Boston Scientific Scimed, Inc. Methods for deploying stents in bifurcations
US6596020B2 (en) * 1996-11-04 2003-07-22 Advanced Stent Technologies, Inc. Method of delivering a stent with a side opening
US6692483B2 (en) * 1996-11-04 2004-02-17 Advanced Stent Technologies, Inc. Catheter with attached flexible side sheath
US5941908A (en) * 1997-04-23 1999-08-24 Vascular Science, Inc. Artificial medical graft with a releasable retainer
US5843027A (en) 1996-12-04 1998-12-01 Cardiovascular Dynamics, Inc. Balloon sheath
DE29701758U1 (en) 1997-02-01 1997-03-27 Jomed Implantate Gmbh Radially expandable stent for implantation in a body vessel, particularly in the area of a vascular branch
US5735859A (en) * 1997-02-14 1998-04-07 Cathco, Inc. Distally attachable and releasable sheath for a stent delivery system
US6071286A (en) * 1997-02-19 2000-06-06 Mawad; Michel E. Combination angioplasty balloon/stent deployment device
US6090128A (en) * 1997-02-20 2000-07-18 Endologix, Inc. Bifurcated vascular graft deployment device
US6096073A (en) * 1997-02-25 2000-08-01 Scimed Life Systems, Inc. Method of deploying a stent at a lesion site located at a bifurcation in a parent vessel
US5893868A (en) 1997-03-05 1999-04-13 Scimed Life Systems, Inc. Catheter with removable balloon protector and stent delivery system with removable stent protector
US6152944A (en) * 1997-03-05 2000-11-28 Scimed Life Systems, Inc. Catheter with removable balloon protector and stent delivery system with removable stent protector
US5824055A (en) 1997-03-25 1998-10-20 Endotex Interventional Systems, Inc. Stent graft delivery system and methods of use
US6143016A (en) * 1997-04-21 2000-11-07 Advanced Cardiovascular Systems, Inc. Sheath and method of use for a stent delivery system
US6013054A (en) 1997-04-28 2000-01-11 Advanced Cardiovascular Systems, Inc. Multifurcated balloon catheter
US5810871A (en) 1997-04-29 1998-09-22 Medtronic, Inc. Stent delivery system
US5957929A (en) * 1997-05-02 1999-09-28 Micro Therapeutics, Inc. Expandable stent apparatus and method
DE29708803U1 (en) * 1997-05-17 1997-07-31 Jomed Implantate Gmbh Radially expandable stent for implantation in a body vessel in the area of a vascular branch
US6221090B1 (en) * 1997-08-13 2001-04-24 Advanced Cardiovascular Systems, Inc. Stent delivery assembly
US6361544B1 (en) * 1997-08-13 2002-03-26 Advanced Cardiovascular Systems, Inc. Stent and catheter assembly and method for treating bifurcations
US6165195A (en) 1997-08-13 2000-12-26 Advanced Cardiovascylar Systems, Inc. Stent and catheter assembly and method for treating bifurcations
US6056722A (en) * 1997-09-18 2000-05-02 Iowa-India Investments Company Limited Of Douglas Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use
US6520988B1 (en) * 1997-09-24 2003-02-18 Medtronic Ave, Inc. Endolumenal prosthesis and method of use in bifurcation regions of body lumens
AU9509498A (en) 1997-09-26 1999-04-12 Corvascular Surgical Systems, Inc. Perfusion-occlusion catheter and methods
US6183432B1 (en) * 1997-11-13 2001-02-06 Lumend, Inc. Guidewire and catheter with rotating and reciprocating symmetrical or asymmetrical distal tip
US5961548A (en) 1997-11-18 1999-10-05 Shmulewitz; Ascher Bifurcated two-part graft and methods of implantation
US6099497A (en) * 1998-03-05 2000-08-08 Scimed Life Systems, Inc. Dilatation and stent delivery system for bifurcation lesions
US6520983B1 (en) * 1998-03-31 2003-02-18 Scimed Life Systems, Inc. Stent delivery system
US6015424A (en) * 1998-04-28 2000-01-18 Microvention, Inc. Apparatus and method for vascular embolization
US6740104B1 (en) * 1998-05-15 2004-05-25 Advanced Cardiovascular Systems, Inc. Enhanced catheter with alignment means
DE19829702C1 (en) * 1998-07-03 2000-03-16 Heraeus Gmbh W C Radially expandable support device V
US6013092A (en) * 1998-08-18 2000-01-11 Baxter International Inc. Folding of catheter-mounted balloons to facilitate non-rotational radial expansion of intraluminal devices
US6117117A (en) * 1998-08-24 2000-09-12 Advanced Cardiovascular Systems, Inc. Bifurcated catheter assembly
US6120522A (en) 1998-08-27 2000-09-19 Scimed Life Systems, Inc. Self-expanding stent delivery catheter
US6514281B1 (en) * 1998-09-04 2003-02-04 Scimed Life Systems, Inc. System for delivering bifurcation stents
US6368345B1 (en) * 1998-09-30 2002-04-09 Edwards Lifesciences Corporation Methods and apparatus for intraluminal placement of a bifurcated intraluminal garafat
US6059813A (en) * 1998-11-06 2000-05-09 Scimed Life Systems, Inc. Rolling membrane stent delivery system
US6660030B2 (en) 1998-12-11 2003-12-09 Endologix, Inc. Bifurcation graft deployment catheter
US6187036B1 (en) * 1998-12-11 2001-02-13 Endologix, Inc. Endoluminal vascular prosthesis
US6190393B1 (en) * 1999-03-29 2001-02-20 Cordis Corporation Direct stent delivery catheter system
US6319275B1 (en) 1999-04-07 2001-11-20 Medtronic Ave, Inc. Endolumenal prosthesis delivery assembly and method of use
US6190360B1 (en) * 1999-04-09 2001-02-20 Endotex Interventional System Stent delivery handle
US6146415A (en) 1999-05-07 2000-11-14 Advanced Cardiovascular Systems, Inc. Stent delivery system
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6884258B2 (en) * 1999-06-04 2005-04-26 Advanced Stent Technologies, Inc. Bifurcation lesion stent delivery using multiple guidewires
US6048350A (en) * 1999-06-14 2000-04-11 Scimed Life Systems, Inc. Segmented balloon delivery system
US6246914B1 (en) * 1999-08-12 2001-06-12 Irvine Biomedical, Inc. High torque catheter and methods thereof
US6471672B1 (en) 1999-11-10 2002-10-29 Scimed Life Systems Selective high pressure dilation balloon
WO2001035715A2 (en) 1999-11-18 2001-05-25 Petrus Besselink Method for placing bifurcated stents
US6224587B1 (en) * 1999-11-22 2001-05-01 C.R. Bard, Inc. Steerable catheter
US6375660B1 (en) * 1999-11-22 2002-04-23 Cordis Corporation Stent delivery system with a fixed guide wire
US6280466B1 (en) * 1999-12-03 2001-08-28 Teramed Inc. Endovascular graft system
US6387120B2 (en) * 1999-12-09 2002-05-14 Advanced Cardiovascular Systems, Inc. Stent and catheter assembly and method for treating bifurcations
US6254593B1 (en) * 1999-12-10 2001-07-03 Advanced Cardiovascular Systems, Inc. Bifurcated stent delivery system having retractable sheath
US6210431B1 (en) * 1999-12-10 2001-04-03 John A. Power Ostial bifurcation lesion stenting catheter
US6361555B1 (en) * 1999-12-15 2002-03-26 Advanced Cardiovascular Systems, Inc. Stent and stent delivery assembly and method of use
US6443926B1 (en) 2000-02-01 2002-09-03 Harold D. Kletschka Embolic protection device having expandable trap
US6391050B1 (en) * 2000-02-29 2002-05-21 Scimed Life Systems, Inc. Self-expanding stent delivery system
US6589262B1 (en) * 2000-03-31 2003-07-08 Medamicus, Inc. Locking catheter introducing system
US6569180B1 (en) * 2000-06-02 2003-05-27 Avantec Vascular Corporation Catheter having exchangeable balloon
US6613067B1 (en) 2000-06-06 2003-09-02 Scimed Life Systems, Inc. Balloon protector
US6482211B1 (en) 2000-07-31 2002-11-19 Advanced Cardiovascular Systems, Inc. Angulated stent delivery system and method of use
US6629992B2 (en) 2000-08-04 2003-10-07 Advanced Cardiovascular Systems, Inc. Sheath for self-expanding stent
US6475166B1 (en) 2000-08-18 2002-11-05 Endovascular Technologies, Inc. Guidewire placement system for delivery of an aneurysm graft limb
US6602226B1 (en) 2000-10-12 2003-08-05 Scimed Life Systems, Inc. Low-profile stent delivery system and apparatus
US6764504B2 (en) 2001-01-04 2004-07-20 Scimed Life Systems, Inc. Combined shaped balloon and stent protector
US6783542B2 (en) 2001-02-22 2004-08-31 Scimed Life Systems, Inc Crimpable balloon/stent protector
EP1258230A3 (en) * 2001-03-29 2003-12-10 CardioSafe Ltd Balloon catheter device
US7422579B2 (en) * 2001-05-01 2008-09-09 St. Jude Medical Cardiology Divison, Inc. Emboli protection devices and related methods of use
US7070613B2 (en) * 2002-01-04 2006-07-04 Boston Scientific Scimed, Inc. Non-compliant balloon with compliant top-layer to protect coated stents during expansion
US7686841B2 (en) 2003-12-29 2010-03-30 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery system
US7922753B2 (en) 2004-01-13 2011-04-12 Boston Scientific Scimed, Inc. Bifurcated stent delivery system
US8012192B2 (en) 2004-02-18 2011-09-06 Boston Scientific Scimed, Inc. Multi-stent delivery system
US20050273149A1 (en) 2004-06-08 2005-12-08 Tran Thomas T Bifurcated stent delivery system

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749825A (en) 1996-09-18 1998-05-12 Isostent, Inc. Means method for treatment of stenosed arterial bifurcations
US6221097B1 (en) 1999-03-22 2001-04-24 Scimed Life System, Inc. Lubricated sleeve material for stent delivery
US6443980B1 (en) 1999-03-22 2002-09-03 Scimed Life Systems, Inc. End sleeve coating for stent delivery
US20020038141A1 (en) 2000-09-22 2002-03-28 Dachuan Yang Sandwich striped sleeve for stent delively
US20020038140A1 (en) 2000-09-22 2002-03-28 Dachuan Yang Hybrid elastomer sleeve for stent delivery
US6554841B1 (en) 2000-09-22 2003-04-29 Scimed Life Systems, Inc. Striped sleeve for stent delivery
US20020072755A1 (en) * 2000-12-08 2002-06-13 Bigus Stephen J. Catheter with rotatable balloon
WO2003017872A1 (en) * 2001-08-23 2003-03-06 Scimed Life Systems Inc Rotating stent delivery system for side branch access and protection and method of using same.
US20040172121A1 (en) * 2003-02-27 2004-09-02 Tracee Eidenschink Rotating balloon expandable sheath bifurcation delivery
WO2004075792A1 (en) * 2003-02-27 2004-09-10 Boston Scientific Limited Stent delivery system with a balloon catheter surrounded by a rotating sheath

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7686841B2 (en) 2003-12-29 2010-03-30 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery system
US7922753B2 (en) 2004-01-13 2011-04-12 Boston Scientific Scimed, Inc. Bifurcated stent delivery system
US8012192B2 (en) 2004-02-18 2011-09-06 Boston Scientific Scimed, Inc. Multi-stent delivery system
WO2006036263A1 (en) * 2004-09-28 2006-04-06 Boston Scientific Limited Rotatable sheath, assembly and method of manufacture of same
US7691137B2 (en) 2004-09-28 2010-04-06 Boston Scientific Scimed, Inc. Rotatable sheath, assembly and method of manufacture of same
WO2010133668A2 (en) 2009-05-20 2010-11-25 Fh Campus Wien Eukaryotic host cell comprising an expression enhancer
US10863997B2 (en) 2016-03-25 2020-12-15 Asahi Intecc Co., Ltd. Medical device

Also Published As

Publication number Publication date
JP4740153B2 (en) 2011-08-03
JP2007516770A (en) 2007-06-28
US20050149161A1 (en) 2005-07-07
EP1708644A1 (en) 2006-10-11
CA2550529A1 (en) 2005-07-28
US7686841B2 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
US7686841B2 (en) Rotating balloon expandable sheath bifurcation delivery system
US8012192B2 (en) Multi-stent delivery system
US7314480B2 (en) Rotating balloon expandable sheath bifurcation delivery
US7922753B2 (en) Bifurcated stent delivery system
US7225518B2 (en) Apparatus for crimping a stent assembly
US7744619B2 (en) Rotatable catheter assembly
EP1758520B1 (en) Stent delivery system
US8177830B2 (en) Rotatable catheter assembly

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2550529

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006546974

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004795507

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004795507

Country of ref document: EP